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A B S T R A C T
Background
Despite medical therapies and surgical interventions for Parkinson’s disease (PD), patients develop progressive disability. The role of
physiotherapy aims to maximise functional ability and minimise secondary complications through movement rehabilitation within a
context of education and support for the whole person. The overall aim is to optimise independence, safety and well-being, thereby
enhancing quality of life.
Objectives
To assess the effectiveness of physiotherapy intervention compared with no intervention in patients with PD.
Search methods
We identified relevant trials by electronic searches of numerous literature databases (e.g. MEDLINE, EMBASE) and trial registers, plus
handsearching of major journals, abstract books, conference proceedings and reference lists of retrieved publications. The literature
search included trials published up to end of December 2010.
Selection criteria
Randomised controlled trials of physiotherapy intervention versus no physiotherapy intervention in patients with PD.
Data collection and analysis
Two review authors independently extracted data from each article. We used standard meta-analysis methods to assess the effectiveness
of physiotherapy intervention compared with no physiotherapy intervention. Trials were classified into the following intervention
comparisons: general physiotherapy, exercise, treadmill training, cueing, dance and martial arts. We used tests for heterogeneity to assess
for differences in treatment effect across these different physiotherapy interventions.
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Main results
We identified 33 trials with 1518 participants. Compared with no-intervention, physiotherapy significantly improved the gait outcomes
of velocity (mean difference 0.05 m/s, 95% confidence interval (CI): 0.02 to 0.07, P = 0.0002), two- or six-minute walk test (16.40
m, CI: 1.90 to 30.90, P = 0.03) and step length (0.03 m, CI: 0 to 0.06, P = 0.04); functional mobility and balance outcomes of Timed
Up & Go test (-0.61 s, CI: -1.06 to -0.17, P = 0.006), Functional Reach Test (2.16 cm, CI: 0.89 to 3.43, P = 0.0008) and Berg
Balance Scale (3.36 points, CI: 1.91 to 4.81, P < 0.00001); and clinician-rated disability using the Unified Parkinson’s Disease Rating
Scale (UPDRS) (total: -4.46 points, CI -7.16 to -1.75, P = 0.001; activities of daily living: -1.36, CI -2.41 to -0.30, P = 0.01; and
motor: -4.09, CI: -5.59 to -2.59, P < 0.00001). There was no difference between arms in falls or patient-rated quality of life. Indirect
comparisons of the different physiotherapy interventions found no evidence that the treatment effect differed across the physiotherapy
interventions for any of the outcomes assessed.
Authors’ conclusions
Benefit for physiotherapy was found in most outcomes over the short-term (i.e. < three months), but was only significant for velocity,
two- or six-minute walk test, step length, Timed Up & Go, Functional Reach Test, Berg Balance Scale and clinician-rated UPDRS.
Most of the observed differences between the treatments were small. However, for some outcomes (e.g. velocity, Berg Balance Scale
and UPDRS), the differences observed were at, or approaching, what are considered minimally clinical important changes.
The review illustrates that a wide range of approaches are employed by physiotherapists to treat PD. However, there was no evidence
of differences in treatment effect between the different types of physiotherapy interventions being used, though this was based on
indirect comparisons. There is a need to develop a consensus menu of ’best-practice’ physiotherapy, and to perform large well-designed
randomised controlled trials to demonstrate the longer-term efficacy and cost-effectiveness of ’best practice’ physiotherapy in PD.
P L A I N L A N G U A G E S U M M A R Y
Physiotherapy for treatment of Parkinson’s disease
In spite of various medical and surgical treatments for Parkinson’s disease (PD), patients gradually develop significant physical problems.
Physiotherapists aim to enable people with PD to maintain their maximum level of mobility, activity and independence through
monitoring their condition and targeting the appropriate treatment. A range of approaches to movement rehabilitation are used, which
aim to enhance quality of life by maximising physical ability and minimising secondary complications over the whole course of the
disease.
Only randomised controlled trialswere included in this review.Thesewere studieswhere a group of participantswere givenphysiotherapy
intervention and compared with another group who did not receive physiotherapy. The participants were assigned to a group in a
random fashion to reduce the potential for bias. Thirty-three randomised trials involving 1518 participants were identified as suitable
for this review. The trials assessed various physiotherapy interventions, so the trials were grouped according to the type of intervention
being used (general physiotherapy, exercise, treadmill training, cueing, dance or martial arts).
There was an improvement with physiotherapy intervention in all walking outcomes (except the 10- or 20-metre walk test). However,
these improvements were only significant for walking speed, walking endurance and step length. Mobility and balance outcomes were
also improved with physiotherapy intervention, with significant improvements in one test of mobility (the Timed Up & Go test which
times how long it takes a person to get up from a chair, walk a certain distance, then walk back to the chair and sit down) and in
two tests of balance (one assessing how far a person can reach before they lose balance (Functional Reach Test) and another which
assesses multiple aspects of balance (Berg Balance Scale)). Clinician-rated disability, using the Unified Parkinson’s Disease Rating Scale
(UPDRS), was also improved with physiotherapy intervention. There was no difference between the two groups in data on falls or
patient-rated quality of life. When comparing the different physiotherapy interventions, there was no evidence that the treatment effect
differed across the physiotherapy interventions for any of the outcomes assessed.
This review provides evidence on the short-term benefit of physiotherapy for the treatment of PD. Although most of the observed
differences were small, the improvements seen for walking speed, balance with the Berg Balance Scale and clinician-rated disability
(using the UPDRS) were of a size that patients would consider an important improvement.
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B A C K G R O U N D
Parkinson’s disease (PD) is a complex neurodegenerative disorder
(Rubenis 2007) with wide-reaching implications for patients and
their families. Whilst disability can occur at all stages of the disease
(Deane 2001a), PD is progressive in nature and so patients face
increased difficulties with activities of daily living (ADL) (Kwakkel
2007) and various aspects of mobility such as gait, transfers, bal-
ance and posture (Keus 2007b). Ultimately, this leads to decreased
independence, inactivity and social isolation (Keus 2007b), result-
ing in reduced quality of life (Schrag 2000).
The management of PD has traditionally centred on drug therapy
with levodopa viewed as the “gold standard” treatment (Rascol
2002). However, even with optimal medical management, pa-
tients with PD still experience a deterioration of body function,
daily activities and participation (Nijkrake 2007). For this reason,
there has been increasing support for the inclusion of rehabilita-
tion therapies as an adjuvant to pharmacological and neurosurgi-
cal treatment (Gage 2004; Nijkrake 2007), and a call for the move
towards multidisciplinary management of this multidimensional
condition (Robertson 2003; Rubenis 2007).
The physiotherapist is a member within this multidisciplinary
team (Robertson 2008; Rubenis 2007), with the purpose of max-
imising functional ability and minimising secondary complica-
tions through movement rehabilitation within a context of ed-
ucation and support for the whole person (Deane 2001a; Plant
2000). Physiotherapy for PD focuses on transfers, posture, upper
limb function, balance (and falls), gait, and physical capacity and
(in)activity, utilising cueing strategies, cognitive movement strate-
gies and exercise to optimise the patient’s independence, safety and
well-being, thereby enhancing quality of life (Keus 2004; Keus
2007a).
Referral rates to physiotherapy for peoplewith PDhave historically
been low (Mutch 1986; Yarrow 1999). However, in recent years,
the number of referrals has increased, with a survey by Parkinson’s
UK in 2008 reporting that 54% of the 13,000 members surveyed
had seen a physiotherapist compared with 27% in a survey un-
dertaken in 1998 (PDS 2008; Yarrow 1999). This rise in referrals
may be attributed to two factors. Firstly, guidelines published by
the National Collaborating Centre for Chronic Conditions (Nat
Collab Centre for Chronic Conditions 2006) recommended that
physiotherapy be made available throughout all stages of the dis-
ease, raising the profile of the profession. This has been further
supported by the publication of Dutch physiotherapy guidelines
(Keus 2004), which provide specific information for physiothera-
pists involved in the management of PD. Secondly, there has been
a substantial increase in the number of trials completed over the
last decade (particularly in the last five years), offering supportive
evidence for the inclusion of physiotherapy in the management of
PD (Keus 2009).
This Cochrane review assessing the effectiveness of physiotherapy
intervention versus no physiotherapy intervention in patients with
PD was first published in 2001, and included only 11 randomised
controlled trials with a total of 280 participants (Deane 2001a).
Most of the trials in the review reported a positive effect in favour
of physiotherapy, but few outcome measures were statistically sig-
nificant. This, combined with the presence of methodological
flaws, small sample sizes, and the possibility of publication bias,
led Deane et al. to conclude that there was insufficient evidence
to support or refute the efficacy of physiotherapy for PD (Deane
2001a). This review updates the previous Cochrane review. We
appraised and synthesised relevant randomised controlled trials,
and we conducted a meta-analysis of outcomes where possible.
O B J E C T I V E S
To compare the effectiveness of physiotherapy intervention versus
no physiotherapy intervention in participants with PD.
To indirectly compare the different physiotherapy interventions
used within the various trials.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all randomised controlled trials (including the first
phase of cross-over trials) comparing a physiotherapy intervention
with no physiotherapy intervention (including placebo-control)
for inclusion in the study. We included trials where the no-inter-
vention arm used an active or credible placebo in the review, as
long as no physiotherapy was delivered to this group. We only
included trials that implemented random methods of treatment
allocation.
Types of participants
Participants with a diagnosis of PD (as defined by the authors of
the studies).
• Any duration of PD
• All ages
• Any drug therapy
• Any duration of physiotherapy treatment
Types of interventions
Physiotherapy interventions aim to maximise functional ability
and minimise secondary complications through movement reha-
bilitation within a context of education and support for the whole
person. Physiotherapy encompasses a wide range of techniques, so
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we were inclusive in our definition of physiotherapy intervention
(including those not delivered by a physiotherapist) with trials of
general physiotherapy, exercise, treadmill training, cueing, dance
and martial arts being included.
Types of outcome measures
1. Gait outcomes such as:
a. Two- or six-minute walk test (m) - measures the number of
metres a person can walk in two or six minutes, thereby providing
a measurement of walking endurance (Kersten 2004).
b. Walking speed:
i. 10- or 20-metre walk test (s) - measures the time in seconds
that a person takes to walk 10 or 20 metres, thereby providing a
measurement of gait speed (Kersten 2004).
ii. Velocity (m/s) - measures the rate of change of position,
recorded in metres per second (Trew 2005).
c. Cadence (steps/min) - measures the number of steps taken in
a given period of time, which is then converted into the number
of steps taken per minute (Trew 2005).
d. Stride length (m) - measures the average distance (in metres)
between two successive placements of the same foot (Whittle
1996).
e. Step length (m) - measures the average distance (in metres)
between successive foot to floor contact with opposite feet (Trew
2005).
f. Freezing of Gait Questionnaire - validated questionnaire
for the assessment of freezing of gait. The questionnaire consists
of six items and scores range from 0 to 24, with higher scores
corresponding to more severe freezing of gait (Giladi 2000).
2. Functional mobility and balance outcomes such as:
a. Timed Up & Go (s) - measures time taken in seconds for
a person to get up from a chair, walk a certain distance (usually
threemetres), turn around and walk back to the chair and sit down
(Podsiadlo 1991).
b. Functional Reach Test (cm) - “the maximal distance one can
reach forward beyond arm’s length, while maintaining a fixed base
of support in the standing position” (Duncan 1990).
c. Berg Balance Scale - validated questionnaire designed to mea-
sure functional standing balance of the older adult. The measure
consists of 14-items and score ranges from 0 to 56; with 0 to 20 =
high fall risk; 21 to 40 = medium fall risk; and 41 to 56 = low fall
risk (Berg 1992; Qutubuddin 2005).
d. Activity Specific Balance Confidence - 16-item self-report
questionnaire that asks individuals to rate their confidence that
they will maintain their balance in the course of daily activities.
Each item is rated from 0% (no confidence) to 100% (complete
confidence) (Powell 1995; Talley 2008).
3. Data on falls such as:
a. Number of patients falling - e.g. falls diary.
b. Falls Efficacy Scale - 10-item patient-reported questionnaire
that measures how confident a person is at carrying out various
activities of daily living (ADL). Items are rated from 1 to 10, with
higher scores correlating with lower levels of confidence, and a
total score of 70 or over indicating that a person has a fear of falling
(Tinetti 1990).
c. Falls Efficacy Scale International - 16-item questionnaire
that includes the 10 original items of the standard Falls Efficacy
Scale as well as six items regarding higher functioning and social
activities. Each item is rated on a scale of 1 to 4, with 1 being ‘not
connected at all’ and 4 ‘very concerned’ (maximum score out of
64) (Yardley 2005).
4. Clinician-rated impairment and disability measures such as:
a. Hoehn & Yahr - scale used to describe how symptoms of
Parkinson’s disease progress. Scale ranges from 0 to 5, with higher
levels indicating greater disability (Hoehn 1967).
b. Unified Parkinson’s Disease Rating Scale (UPDRS) - designed
to assess motor impairment and disability in Parkinson’s disease.
Higher scores correspond to greater disability (Fahn 1987).
i. total - score ranges from 0 to 176.
ii. mental - score ranges from 0 to 16.
iii. ADL - score ranges from 0 to 52.
iv. motor - score ranges from 0 to 108.
c. Webster Rating Scale - Assessment of severity of disease and
clinical impairment against 10 items using a scale of 0 = normal to
3 = maximum impairment: bradykinesia, rigidity, posture, upper
extremity swing, gait, tremor at rest, facies, seborrhoea, speech, and
self care. Score ranges from 0 to 30, with higher scores indicating
greater disease severity and disability (Webster 1968).
d. Columbia University Rating Scale - Assessment of motor
impairment and activities of daily living against 13 items, using a
five-point scale for each to give a total score between 0 = normal
to 65 = maximum disability (Yahr 1969).
5. Patient-rated quality of life such as:
a. Parkinson’sDiseaseQuestionnaire - 39 (PDQ-39) - PD specific
health-related quality of life questionnaire containing 39 items
divided between eight domains. Scores range from 0 to 100 with
higher scores corresponding to poorer quality of life (Jenkinson
1997; Peto 1995).
b. PDQUALIF - PD specific health-related quality of life ques-
tionnaire containing 32 items in seven dimensions and one item
of global health-related quality of life. Total score ranges from 0
to 128 with higher scores indicating poorer quality of life (Welsh
2003).
c. PDQL - PD specific health-related quality of life questionnaire
containing 37 items grouped into four subscales. Item scores range
from 1 to 5. The PDQL-Summary Index ranges from 37 to 185,
with higher scores reflecting better quality of life (Deboer 1996).
d. Short Form-36 or 12 - Generic short form health survey con-
sisting of 36 or 12 questions. The SF-36 consists of eight scaled
scores assessing vitality, physical functioning, bodily pain, general
health perceptions, physical role functioning, emotional role func-
tioning, social role functioning and mental health. Scores range
from 0 to 100 with higher scores corresponding to better quality
of life (Ware 1992).
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6. Adverse events e.g. fractures, pain.
7. Compliance e.g. participant adherence, treatment fidelity.
8. Economic analysis.
Search methods for identification of studies
The review is based on the Movement Disorders Group search
strategy and also the following more general search strategy:
a. Physiotherapy OR physical therapy OR exercise OR reha-
bilitation.
b. Parkinson OR Parkinson’s disease OR Parkinsonism.
c. #a AND #b.
Further details on this search strategy are available in the Group’s
module within The Cochrane Library (www.cochrane.org). This
includes explanations of the acronyms, sources and websites.
We undertook a systematic search of the literature up to the end of
December 2010 for publications or abstracts describing relevant
trials. This included searching:
1. General biomedical and science electronic databases (without
date limiters) including the Movement Disorders Review Group
Specialized Register, The Cochrane Library, MEDLINE (1966-
2010), EMBASE (1974-2010), CINAHL (1982-2010), ISI-SCI
(1981-2010); rehabilitation databases: AMED (1985-2010), RE-
HABDATA (1995-2010), REHADAT, GEROLIT (1979-2010);
English language databases of foreign language research and third
world publications: LILACS (1982-2010), MedCarib (17th Cen-
tury-2010) and IMEMR (1984-2010).
2. The Cochrane Controlled Trials Register, the CentreWatch
Clinical Trials listing service, themetaRegister ofControlledTrials,
ClinicalTrials.gov, RePORT, PEDro, NIDRR and NRR.
3. Handsearching of general (Lancet, BMJ, JAMA) and spe-
cific journals (Movement Disorders, Neurology, Archives of Physical
Medicine and Rehabilitation, Clinical Rehabilitation, Physiotherapy,
Physical Therapy) from 2001 to the end of 2010.
4. The reference lists of retrieved papers and review articles.
5. Abstract books and conference proceedings. This included
The XIII International Congress on Parkinson’s disease (1999),
The International Congress of Parkinson’s Disease andMovement
Disorders (1990, 92, 94, 96, 98, 2000, 02, 04, 05, 06, 07, 08, 09,
10),WorldCongress on Parkinson’sDisease and RelatedDisorders
(2009) and The American Academy of Neurology 51st annual
meeting (1999).
6. Grey literature databases (including theses): Conference Pro-
ceedings Citation Index (1982-2010), DISSABS (1999-2010),
Conference Papers Index (1982-2010), Index to Theses (1970-
2010), Electronic ThesesOnline Service (EThOS) (16th Century-
2010) and ProQuest dissertations and theses databases (1861-
2010).
Data collection and analysis
Selection of studies
Abstracts of potentially relevant studies from search results were
each screened by two of the three review authors involved in study
selection (CT, SP, LS). The full paper was obtained if the abstract
did not provide sufficient information to determine eligibility for
inclusion in the review.Disagreementwas resolved by referral to an
additional review author (RS).We contacted authors of potentially
eligible studies for further information if details of their trial were
unclear.
Data extraction and management
Three review authors (CT, SP or CM) independently assessed the
identified papers and abstracts for trial details and outcome data,
each eligible study was considered by two of these three authors.
This was validated by discussionwith any discrepancies resolved by
consensus. We recorded trial details on a standard trial description
form and included: trial name, trial group, authors, randomised
comparison, treatment schedule (including duration, number of
sessions, type of intervention), other therapy, eligibility criteria,
method of randomisation, allocation concealment, blinding, ac-
crual period, number of participants randomised, number of drop
outs, duration of follow-up, outcomes reported, use of intention-
to-treat analysis and publication date(s). Outcome data extracted
included data on gait, functional mobility and balance, falls, clin-
ician-rated disability scale and patient-rated quality of life, ad-
verse events, compliance/withdrawals and health economics where
available.
We contacted the authors of any eligible unpublished studies to
ask if further details and data for their trial could be provided.
Assessment of risk of bias in included studies
We assessed the full papers for methodological quality by record-
ing eligibility criteria, method of randomisation and blinding,
concealment of allocation, similarity of participants in treatment
groups at baseline, co-intervention(s) constant, use of active or
credible placebo, whether an intention-to-treat analysis was per-
formed and the number of participants lost to follow-up and
missing values (see ’Risk of bias’ tables under Characteristics of
included studies).
Data synthesis
We combined the results of each trial using standard meta-analytic
methods to estimate an overall effect for physiotherapy interven-
tion versus no physiotherapy intervention.
All outcomes with data available for meta-analysis were continu-
ous variables, so we calculated the mean difference between treat-
ment arms using mean difference methods (Fleiss 1993). In sum-
mary, this involved for each trial, calculating the mean change
(and standard deviation) from baseline to the post-intervention
time point for both the intervention and no-intervention groups.
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From these, the mean difference and its variance between arms
for each trial could be calculated. In some studies, the standard
deviation for the mean change was not reported, in these cases
we imputed this standard deviation using the standard deviations
for the baseline and final scores. To do this we used the following
formula to estimate the variance of the change in score:
var diff = var pre + var post - 2r
√
(var pre var post )
where var diff is the variance of the change score; var pre is the
variance of the baseline score; var post is the variance of the final
score and r is the correlation between the pre- and post-treatment
scores. We assumed a correlation co-efficient of 0.5, which is a
conservative estimate, to reduce the chance of false positive results
(Higgins 2011).
These values were then combined using weighted mean difference
methods to give the overall pooled estimate of the mean differ-
ence, with 95% confidence interval, for physiotherapy interven-
tion versus no physiotherapy intervention (control).
If any trials with three or more intervention arms were identified,
then we made the following assumptions for the analysis:
1. If the trial was comparing two or more physiotherapy inter-
ventions within the same classification (see subgroup analysis be-
low) versus no intervention, then we combined the data for these
physiotherapy interventions to give one comparison of physio-
therapy intervention versus no intervention.
2. If the trial was comparing two or more physiotherapy in-
terventions in different classifications versus no intervention, then
we included the trial in each relevant physiotherapy intervention
classification. This meant that some trials were included multiple
times in the analysis, and the control arms from these trials were
counted more than once in the analysis.
The primary analysis was a comparison of physiotherapy interven-
tion versus no physiotherapy intervention (control) using change
from baseline to the first assessment after the treatment period
(which in most cases was immediately post intervention). This
was chosen as the primary analysis for this review, as in most trials
this was the main data analysis, and few trials reported data at
longer-term assessment points (i.e. after six months). Also, some
trials allowed participants in the no-intervention arm to receive
physiotherapy intervention after this point. So this allowed a clean
comparison of physiotherapy intervention versus no physiother-
apy intervention.
Subgroup analysis and investigation of heterogeneity
The different trials implemented various types of physiotherapy
intervention. Therefore trials were divided according to the type
of intervention administered:
1. general physiotherapy versus control;
2. exercise versus control;
3. treadmill versus control;
4. cueing versus control;
5. dance versus control;
6. martial arts versus control.
To assess for differences between the different types of interven-
tions involved, we used indirect comparisons using tests of hetero-
geneity and I2 values to investigate whether the treatment effect
differed across the different interventions (Deeks 2001; Higgins
2003). The I2 value describes the percentage of the variability in
effect estimates that is due to heterogeneity rather than sampling
error (chance) (Higgins 2003). These testsmay suggest the possible
superiority of one type of intervention over another, and may pro-
vide clinicians and patients with more reliable information upon
which to base decisions about therapy. However, as with all sub-
group comparisons, these analyses should be interpreted with cau-
tion and should be considered hypothesis generating (Assmann
2000; Clarke 2001).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
We identified 61 randomised trials of physiotherapy intervention
in PD patients. We excluded 22 studies (see Characteristics of
excluded studies). The reasons for excluding these trials were cross-
over study with data not presented for the first treatment period
or cross-over was over a short period e.g. one day (n = 4); not ran-
domised or not properly randomised (n = 6); no outcomemeasures
relevant to our review (n = 4); multidisciplinary therapy rehabili-
tation trial (n = 4); study was confounded (n = 2); and treatment
given in trial not usually used by physiotherapists (n = 2). There
were also six ongoing trials for which data were not yet available
(see Characteristics of ongoing studies). Therefore, there were 33
trials available for inclusion in the review compared with 11 in the
2001 review (Figure 1).
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Figure 1. Study PRISMA flow diagram.
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The number of participants randomised into the 33 trials ranged
from six to 153 participants, with 1518 participants randomised
in total (giving an average trial size of nearly 50 participants) (
Characteristics of included studies). The assessment period ranged
from three weeks to 12 months. The mean age of participants in
the trials was 67 years, 64% were male, the mean Hoehn & Yahr
stage was 2.4, and they had had PD for approximately six years
(Table 1).
There was one trial comparing walking on treadmill listening to
music versus walking on treadmill without music versus listening
tomusic alone (Shankar 2009).We excluded the treadmill without
music arm of this trial from the analysis as this was a confounded
comparison.
There were two three-arm trials comparing two exercise interven-
tions with control. One compared exercise versus exercise and ed-
ucation versus control (Klassen 2007), and the other compared
exercise versus PD SAFEx versus control (Sage 2009a). The exer-
cise interventions being compared in these studies were considered
suitably similar, so we combined the data from the two exercise
arms within each trial to give one comparison of exercise versus
control. There was also one four-arm trial comparing two types of
dance (waltz/foxtrot and tango) and martial arts with control. We
combined the two dance arms to give one comparison of dance
versus control, as well as a martial arts versus control comparison
(Hackney 2009).
There were three other three-arm trials that contributed data to
two of the different physiotherapy intervention comparisons. Two
of these were trials of cueing versus exercise versus control, which
contributed to both the cueing versus control and exercise versus
control comparisons (Mak 2008; Thaut 1996). The other trial was
of treadmill versus general physiotherapy versus control, which
contributed to both the treadmill versus control and general phys-
iotherapy versus control comparisons (Fisher 2008). The 33 trials
therefore contributed data to 37 comparisons within the six differ-
ent types of physiotherapy interventions - general physiotherapy
versus control (n = 5), exercise versus control (n = 12), treadmill
versus control (n = 7), cueing versus control (n = 7), dance versus
control (n = 2) and martial arts versus control (n = 4).
General physiotherapy versus control
The five trials of general physiotherapy versus control involved 197
participants (Chandler 1999; Ellis 2005; Fisher 2008; Homann
1998; Keus 2007b). The mean participant age was 65 years, 70%
were male, the mean Hoehn & Yahr stage was 2.3 and mean dura-
tion of PD was four years. All the trials were parallel-group design,
except one which was a cross-over design (Ellis 2005). Treatment
sessions took place over a period of five weeks to 12 months; dura-
tion of sessions was only described by one trial (Ellis 2005). One
trial used Bobath training for gait and posture (Homann 1998).
The remaining trials provided multifaceted interventions encom-
passing movement strategies, exercise, hands-on techniques, edu-
cation and advice, targeting a wide range of areas including gait,
balance, transfers, posture and physical fitness. Thus, general phys-
iotherapy is a holistic intervention and on the whole uses a com-
bination of techniques which does not routinely include comple-
mentary and/or alternative medicine such as acupuncture or hyp-
notherapy.
Exercise versus control
The 12 trials of exercise versus control involved 635 participants
(Allen 2010; Ashburn 2007; Cerri 1994; Goodwin 2009; Klassen
2007; Mak 2008; Meek 2010; Sage 2009a; Schenkman 1998;
Schilling 2008; Stozek 2003; Thaut 1996). The mean participant
age was 67 years, 63% were male, the mean Hoehn & Yahr stage
was 2.4 and mean duration of PD was six years. All the trials were
parallel-group design. Treatment sessions lasted from 30 minutes
to two hours, and took place over a period of three to 24weeks. Ex-
ercise involved a variety of different activities including strength-
ening and balance training, walking, falls prevention, neuromus-
cular facilitation, resistance exercise and aerobic training as well as
education and relaxation techniques. Although sometimes multi-
faceted, the primary focus of these interventionswas exercise deliv-
ery, and treatment was frequently categorised by the trial authors
as this.
Treadmill versus control
The seven trials of treadmill versus control involved 179 partici-
pants (Cakit 2007; Canning 2008; Fisher 2008; Ganesan 2010;
Kurtais 2008; Protas 2005; Shankar 2009). The mean partici-
pant age was 67 years, 68% were male, the mean Hoehn & Yahr
stage was 2.4 and mean duration of PD was five years. All the
trials were parallel-group design. Treatment sessions lasted from
30 to 60 minutes, and took place over a period of four to eight
weeks. Treadmill training mainly involved participants walking on
a treadmill with speed and/or incline adjustments. Two trials used
body weight supported treadmill training (Fisher 2008; Ganesan
2010) and two other trials provided gait and step training (Kurtais
2008; Protas 2005).
Cueing versus control
The seven trials of cueing versus control involved 303 participants
(de Bruin 2010a; de Bruin 2010b; Lehman 2005; Mak 2008;
Nieuwboer 2007; Shankar 2008; Thaut 1996). The mean partic-
ipant age was 68 years, 60% were male, the mean Hoehn & Yahr
stage was 2.5 and mean duration of PD was seven years. Six of
the trials were parallel-group design and one was a cross-over de-
sign (Nieuwboer 2007). Treatment sessions lasted from 20 to 30
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minutes and took place over a period of two to 13 weeks. There
were three types of cueing used in the trials - audio (music, spoken
instructions), visual (computer images) and sensory (vibration).
Six trials applied external cues during gait or gait-related activity,
whilst Mak (Mak 2008) utilised cues for the rehabilitation of sit-
to-stand transfers.
Dance versus control
The two trials of dance versus control involved 120 participants
(Earhart 2010; Hackney 2009). The mean participant age was 69
years, 64% were male, the mean Hoehn & Yahr stage was 2.3 and
mean duration of PD was seven years. Both trials had a parallel-
group design. Dance classes lasted one hour over 12 to 13 weeks,
with a trained instructor teaching participants the tango, waltz or
foxtrot.
Martial arts versus control
The four trials of martial arts versus control involved 143 par-
ticipants (Hackney 2009; Marjama-Lyons 2002; Purchas 2007;
Schmitz-Hubsch 2006). The mean participant age was 66 years,
72% were male, the mean Hoehn & Yahr stage was 2.1 and mean
duration of PD was seven years. All the trials were parallel-group
design, except one which was a cross-over design (Purchas 2007).
Treatment lasted one hour and took place over a period of 12 to 24
weeks. Participants took classes on Tai Chi (three trials; Hackney
2009; Marjama-Lyons 2002; Purchas 2007) or Qigong (one trial;
Schmitz-Hubsch 2006).
Risk of bias in included studies
See Characteristics of included studies, risk of bias in included
studies tables, risk of bias graph (Figure 2).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Trial design
Thirty trials had a parallel design and three had a cross-over design
(Ellis 2005; Nieuwboer 2007; Purchas 2007). The cross-over trials
had no washout period, with participants assessed at baseline, after
the first treatment period, and then after the second treatment
period. Most trials looked at the short-term effect of therapy by
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assessing the participants at baseline and immediately or shortly
after the physiotherapy intervention period (which ranged from
two to 52weeks). Eight of the parallel design trials (Ashburn 2007;
Goodwin 2009; Klassen 2007; Lehman 2005; Mak 2008; Meek
2010; Schmitz-Hubsch 2006; Stozek 2003) reported additional
data at assessment points after the treatment period had finished;
this may have been at only one week or up to 12 months after the
end of the treatment period.
Sample size
Only four studies (12%; Allen 2010; Ashburn 2007; Ellis 2005;
Nieuwboer 2007) reported a sample size calculation in the trial
report, which was achieved by all but one study (Ashburn 2007).
Eligibility criteria
The eligibility criteria for the trials were broad and varied con-
siderably across the trials. The level of detail provided on the el-
igibility criteria was also variable, with some studies providing a
detailed description of the entry criteria, and others just stating
“patients with Parkinson’s disease”. Only seven trials (Cakit 2007;
de Bruin 2010a; Homann 1998; Keus 2007b; Nieuwboer 2007;
Schmitz-Hubsch 2006; Shankar 2008) stated that a diagnosis of
PD by the United Kingdom Brain Bank Criteria (Gibb 1988) was
required. It is vital that eligibility criteria are well-defined, so that
the trial participant population can be determined.
Randomisation method and concealment of
allocation
Only fourteen trials (42%) described the randomisation method
used, of which nine trials used low risk methods (e.g. block ran-
domisation or computer random number generators). No details
on the randomisation method used were provided for the remain-
ing nineteen trials. Further, only 11 trials (33%) either stated or
gave adequate information that allowed the assessment of whether
an adequate concealment of treatment allocation procedure had
been used. Five trials were considered to be low risk by virtue of
having used a central randomisation service with the other six con-
sidered high risk (i.e. concealment of treatment allocation was po-
tentially compromised - sealed envelopes, picking card or picking
from a hat).
Blinding of assessors
It would be impossible to blind participants and therapists to ran-
domised treatment allocation in trials of physiotherapy. There-
fore, such trials are open label by nature, and are consequently
liable to the possibility of both performance and attrition bias.
However, blinding of assessors could be employed to try and re-
duce the possibility of bias. Twenty-one (64%) of the 33 studies
used blinded assessors (though in one study the assessors correctly
guessed the treatment allocation in nearly 30% of patients (un-
clear risk; Ashburn 2007), two used un-blinded assessors so were
classed as high risk, and in the other 10 studies this information
was not provided (classed as unclear risk).
Description of the no-intervention (control) group
In most trials (n = 29), the control group did not receive any phys-
iotherapy treatment or intervention, however in four trials (Allen
2010; Ashburn 2007; Fisher 2008; Shankar 2009) an active or
credible placebo that attempted to control for the time and atten-
tion involved in receiving physiotherapy intervention compared
with no treatment was used. This included contact with a PD
nurse, education classes, advice on falls prevention or listening to
music. The control groups were followed up and assessed in the
same manner as the intervention groups.
Co-interventions
Information on co-interventions was provided in 19 trials (58%),
with participants continuing with their standard PD medication.
In 12 trials, this drug therapy was kept stable (low risk) through-
out the duration of the trial, whereas seven trials allowed variation
(unclear risk). The remaining 14 trials did not describe drug ther-
apy (unclear risk).
Similarity of treatment groups at baseline
A description of the baseline characteristics of the trial participants
is important to determine whether the trial results are generalisable
and to compare characteristics of the two arms to ensure that the
randomisation methods were successful.
Four trials (de Bruin 2010b; Ganesan 2010; Homann 1998;
Marjama-Lyons 2002) did not provide any information on the
baseline characteristics of the participants entered into the trial.
Twenty-three (of the 29) trials that reported baseline data gave
this information split by treatment group and showed participants
to be similar at baseline. In nine trials, the baseline characteris-
tics of the withdrawn participants were not given (Cakit 2007; de
Bruin 2010a; Hackney 2009; Klassen 2007; Kurtais 2008; Mak
2008; Purchas 2007; Sage 2009a; Schenkman 1998). This, along
with the four studies that did not supply baseline data, meant that
151 (10%) of the 1518 randomised participants were not charac-
terised.
Data analysis
Eight trials stated intention-to-treat as the primary method of
analysis, although it was not always clear if patients who withdrew
from the trial were included in the analysis. The number of patient
withdrawals was classed as low risk (≤ 10% of trial participants
withdrew) in six of the eight trials. In the other 25 trials, the
method of analysis was not described (unclear risk). Of these trials,
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11 were considered high risk in terms of the proportion of patients
that withdrew (i.e. > 10%), and in 12 trials the number of patient
withdrawals (if any) was not described (unclear risk).
Data available for analysis
Thirteen trials were reported in abstract form. We requested
further information from authors with seven (Canning 2008;
Earhart 2010;Goodwin 2009; Klassen 2007;Meek 2010; Purchas
2007; Shankar 2008) providing additional information and six
(Cerri 1994; de Bruin 2010b; Ganesan 2010; Homann 1998;
Marjama-Lyons 2002; Shankar 2009) requests being unsuccessful.
However, sufficient data were available for meta-analysis for five
of the 13 studies (Earhart 2010; Goodwin 2009; Klassen 2007;
Meek 2010; Shankar 2009). Further, one trial had relevant data
which could not be extracted as they were only available in graph
form (Lehman 2005). Therefore data were not available for meta-
analysis for nine trials, meaning that of the 33 trials, data available
for analysis were provided by 24 trials.
Effects of interventions
Primary analysis
Gait outcomes
Two-or six-minute walk test (m)
Data on the two- or six-minute walk test were available from four
trials for five comparisons within three physiotherapy interven-
tions (exercise, dance andmartial arts). (Note: Hackney 2009 con-
tributed data to both the dance and martial arts comparisons).
One hundred and seventy-two participants were included in this
analysis. There was a benefit of borderline significance, with a
greater increase in the distance walked in two or six minutes with
physiotherapy intervention compared with no intervention (mean
difference 16.40 m, 95% confidence interval (CI) 1.90 to 30.90;
P = 0.03). There was no evidence of heterogeneity between the
individual trials (P = 0.37, I2 = 7%), nor was there evidence that
the treatment effect differed across the three physiotherapy inter-
ventions (P = 0.14, I2 = 49%).
Ten- or 20-metre walk test (s)
Data on the 10- or 20-metre walk test were available from four
trials for two physiotherapy interventions (exercise and treadmill).
One hundred and sixty-nine participants were included in the
analysis. There was borderline significance in favour of no inter-
vention for the time taken to walk 10 or 20 metres (0.40 s, CI
0.00 to 0.80; P = 0.05). There was no evidence of heterogeneity
between the individual trials (P = 0.19, I2 = 38%), nor was there
evidence that the treatment effect differed across the two physio-
therapy interventions (P = 0.51, I2 = 0%).
Velocity (m/s)
Data on velocity were available from 11 trials for 15 comparisons
within all six physiotherapy interventions. (Note: Fisher 2008;
Hackney 2009; Mak 2008; and Thaut 1996 all contributed data
to two physiotherapy comparisons). Six hundred and twenty-nine
participants were included in this analysis. There was a significant
benefit for physiotherapy, with velocity increased by 5 cm/second
with physiotherapy intervention compared with no intervention
(0.05m/s, CI 0.02 to 0.07; P = 0.0002, see Figure 3). There was no
evidence of heterogeneity between the individual trials (P = 0.44,
I2 = 1%), nor was there any evidence of heterogeneity between
the different types of physiotherapy intervention (P = 0.24, I2 =
25.9%).
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Figure 3. Velocity (m/s).
Cadence (steps/min)
Data on cadence were available from six trials for eight compar-
isonswithin four physiotherapy interventions (general physiother-
apy, exercise, treadmill and cueing). (Note: Fisher 2008 and Thaut
1996 contributed data to two physiotherapy comparisons). Three
hundred and twenty-seven participants were included in this anal-
ysis. There was no significant difference in cadence between the
two treatment arms (-1.72 steps/min, CI -4.01 to 0.58; P = 0.14).
Stride length (m)
Data on stride length were available from five trials for eight com-
parisons within all six physiotherapy interventions. (Note: Fisher
2008, Hackney 2009 and Thaut 1996 contributed data to two
physiotherapy comparisons). Two hundred and two participants
were included in this analysis. There was no difference in stride
length between the two treatment arms (0.03 m, CI -0.02, 0.09;
P = 0.26).
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Step length (m)
Data on step length were available from three trials for four com-
parisons within four physiotherapy interventions (general physio-
therapy, exercise, treadmill and cueing). (Note: Fisher 2008 con-
tributed data to both the general physiotherapy and treadmill
comparisons). Two hundred and thirty-nine participants were in-
cluded in this analysis. There was a borderline significant benefit,
with step length increased by 3 cm with physiotherapy interven-
tion compared with no intervention (0.03 m, CI 0.00 to 0.06;
P = 0.04). There was no evidence of heterogeneity between the
individual trials (P = 0.60, I2 = 0%), nor was there evidence that
the treatment effect differed across the four physiotherapy inter-
ventions (P = 0.60, I2 = 0%).
Freezing of Gait Questionnaire
Data from the Freezing of Gait Questionnaire were available from
just three trials for three physiotherapy interventions (exercise,
cueing and dance). Two hundred and forty-six participants were
included in this analysis. There was no significant difference be-
tween the two treatment arms (-1.19, CI -2.54 to 0.16; P = 0.08).
Functional Mobility and Balance Outcomes
Timed Up & Go (s)
Data on the Timed Up & Go test were available from seven tri-
als for eight comparisons within four physiotherapy interventions
(exercise, cueing, dance and martial arts). (Note: Hackney 2009
contributed data to both the dance and martial arts comparisons).
Four hundred and ninety-five participants were included in this
analysis. Overall, the time taken to complete the Timed Up&Go
test was significantly improved (i.e. reduced) with physiotherapy
intervention compared with no intervention (-0.61 s, CI -1.06
to -0.17; P = 0.006, see Figure 4). There was no heterogeneity
between the individual trials (P = 0.07, I2 = 46%), nor between
the four physiotherapy interventions (P = 0.34, I2 = 9.9%).
Figure 4. Timed Up & Go (s).
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The results for the Hackney et al. martial arts comparison were
heavily weighted in the analysis (54.1%), due to very small stan-
dard deviations (Hackney 2009) compared with the other studies.
It was also noted that in the trial publication, a non-significant (P =
0.093) effect of martial arts intervention was reported, which was
in contrast to our data analysis which reported a significant im-
provement (P = 0.003). We contacted the author to check whether
the data reported in the paper were in fact standard errors, but they
were confirmed as standard deviations. We therefore performed a
sensitivity analysis removing this study and found that the overall
result became non-significant (-0.28 s, CI -0.93 to 0.37; P = 0.40),
so this data perhaps need to be interpreted with caution.
Functional Reach Test (cm)
Data on the Functional Reach Test were available from four trials
for two physiotherapy interventions (exercise and cueing). Three
hundred and ninety-three participants were included in this anal-
ysis. Functional reach was significantly improved with physiother-
apy intervention compared with no intervention (2.16 cm, CI
0.89 to 3.43; P = 0.0008). There was no evidence of heterogeneity
between the individual trials (P = 0.15, I2 = 44%), nor was there
evidence that the treatment effect differed across the two physio-
therapy interventions (P = 0.48, I2 = 0%).
Berg Balance Scale
Data on the Berg Balance Scale were available from four trials
for five comparisons within four physiotherapy interventions (ex-
ercise, treadmill, dance and martial arts). (Note: Hackney 2009
contributed data to both the dance and martial arts comparisons).
Three hundred and sixty-one participants were included in this
analysis. The Berg Balance Scale was significantly better follow-
ing physiotherapy intervention (3.36 points, CI 1.91 to 4.81; P
< 0.00001). There was no evidence of heterogeneity between the
individual trials (P = 0.16, I2 = 40%), nor was there evidence that
the treatment effect differed across the four physiotherapy inter-
ventions (P = 0.21, I2 = 33%).
Activity Specific Balance Confidence
Data on Activity Specific Balance Confidence were available from
three trials for two physiotherapy interventions (exercise and cue-
ing). Sixty-six participants were included in this analysis. There
was no difference between the two treatment arms (2.40 points,
CI -2.78 to 7.57; P = 0.36).
Falls
Number of falls
Seven trials (Ashburn 2007; Goodwin 2009; Marjama-Lyons
2002; Meek 2010; Nieuwboer 2007; Protas 2005; Purchas 2007)
attempted to record the number of falls during the trial period.
This was usually by means of a falls diary, which can be difficult to
analyse and subject to bias. Nevertheless, most of the individual
trials reported a general trend for a reduction in the number of
falls with intervention. However, when this was compared with
the no-intervention arm this was not significant, except in one
trial. Marjama-Lyons 2002 reported a significant decrease in the
chance of fall frequency with Tai Chi intervention when compared
with no intervention.
Falls Efficacy Scale
Data on the Falls Efficacy Scale were available from four trials for
four comparisons within two physiotherapy interventions (exer-
cise and cueing). Three hundred and fifty-three participants were
included in this analysis. There was no difference in the Falls Ef-
ficacy Scale between the two treatment arms (-1.91 points, CI -
4.76 to 0.94; P = 0.19).
Clinician-rated disability
Only data on the Unified Parkinson’s Disease Rating Scale were
available for meta-analysis.
Unified Parkinson’s Disease Rating Scale (UPDRS)
Total
Data on total UPDRS score were available from two trials for
three comparisons within two physiotherapy interventions (gen-
eral physiotherapy and treadmill). (Note: Fisher 2008 contributed
data to both the general physiotherapy and treadmill compar-
isons). One hundred and five participants were included in this
analysis. Overall, the UPDRS total score was significantly im-
proved with physiotherapy intervention compared with no inter-
vention (-4.46 points, CI -7.16 to -1.75; P = 0.001). There was
no evidence of heterogeneity between the individual trials (P =
0.45, I2 = 0%), nor was there evidence of heterogeneity between
the different types of physiotherapy intervention (P = 0.29, I2 =
9.6%).
Mental
Data on the mental sub-scale of the UPDRS were available from
two trials for three comparisons within two physiotherapy in-
terventions (general physiotherapy and treadmill). (Note: Fisher
2008 contributed data to both the general physiotherapy and
treadmill comparisons). One hundred and five participants were
included in this analysis. There was no difference in UPDRSmen-
tal score between the two treatment arms (-0.44, CI -0.98 to 0.09;
P = 0.10).
Activities of daily living (ADL)
Data on the ADL sub-scale of the UPDRS were available from
three trials for four comparisons within three physiotherapy in-
terventions (general physiotherapy, treadmill and dance). (Note:
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Fisher 2008 contributed data to both the general physiotherapy
and treadmill comparisons). One hundred and fifty-seven partic-
ipants were included in this analysis. Overall, the UPDRS ADL
score was significantly improved with physiotherapy intervention
compared with no intervention (-1.36 points, CI -2.41 to -0.30;
P = 0.01). There was no evidence of heterogeneity between the
individual trials (P = 0.28, I2 = 22%), nor was there any evidence
of heterogeneity between the different types of physiotherapy in-
tervention (P = 0.19, I2 = 40.1%).
Motor
Data on the motor sub-scale of the UPDRS were available from
nine trials for eleven comparisons within all six physiotherapy
interventions. (Note: Fisher 2008 and Hackney 2009 both con-
tributed data to two physiotherapy interventions). Four hundred
and thirty-one participants were included in this analysis. Overall,
the UPDRS motor score was significantly improved with physio-
therapy intervention comparedwith no intervention (-4.09points,
CI -5.59 to -2.59; P < 0.00001, see Figure 5). There was no evi-
dence of heterogeneity between the individual trials (P = 0.92, I
2 = 0%), nor was there evidence that the treatment effect differed
across the six physiotherapy interventions (P = 0.61, I2 = 0%).
Figure 5. UPDRS - Motor.Earhart 2010, MDS-UPDRS
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Patient-rated quality of life
Only data on the Parkinson’s Disease Questionnaire - 39 (PDQ-
39) for the mobility domain and summary index were available
for meta-analysis.
Parkinson’s Disease Questionnaire - 39 (PDQ-39)
Summary Index
Data on the Summary Index of the PDQ-39 were available from
six trials for seven comparisonswithin five physiotherapy interven-
tions (general physiotherapy, exercise, cueing, dance and martial
arts). (Note: Hackney 2009 contributed data to both the dance
and martial arts comparisons). Three hundred and eighty-seven
participants were included in this analysis. There was no difference
between treatment arms in patient-rated quality of life following
physiotherapy intervention (-0.35 points, CI -2.66 to 1.96; P =
0.77).
Mobility
Data on the mobility domain of the PDQ-39 were available from
two trials for three comparisons within three physiotherapy inter-
ventions (general physiotherapy, dance and martial arts). (Note:
Hackney 2009 contributed data to both the dance and martial arts
comparisons). One hundred and five participants were included
in this analysis. There was no difference in the PDQ-39 mobility
score between the two treatment arms (-1.43, CI -8.03 to 5.18; P
= 0.67).
Adverse Events
No trials reported data on adverse events.
Compliance
Only eleven trials of the 33 discussed patient compliance with
eight (Allen 2010; Ellis 2005; Keus 2007b; Klassen 2007; Kurtais
2008; Meek 2010; Sage 2009a; Schenkman 1998) quantifying it
in some form, however, this was difficult to analyse.
Health economic
No trials reported data on health economic outcomes.
Subgroup analysis
There was no evidence of any differences in the treatment effect
between the different physiotherapy interventions used in the var-
ious trials for any of the outcomes assessed.
D I S C U S S I O N
Summary of main results
This review updates the previous Cochrane review published in
2001 (Deane 2001a) comparing physiotherapy intervention ver-
sus no physiotherapy intervention for the treatment of PD. The
review now includes 33 randomised trials with 1518 participants
(compared with 11 trials and 280 participants in the 2001 re-
view). It also reports the comparison of the different types of phys-
iotherapy interventions used in the treatment of PD, and thus
provides a comprehensive assessment of physiotherapy treatment.
Many recent systematic reviews have focused on specific areas of
physiotherapy such as exercise and cueing (Crizzle 2006;Goodwin
2008; Lim 2005; Nieuwboer 2008). Nowadays, physiotherapy for
PD encompasses a wide range of methods and techniques rang-
ing from standard NHS physiotherapy to exercise regimens and
martial arts. Therefore, it is important that all forms of physio-
therapy intervention are included, so that the true benefit (if any)
of physiotherapy can be assessed. The review also includes a more
comprehensive range of outcome measures compared with previ-
ous reviews (18 outcomes assessing gait, functional mobility and
balance, falls, clinician-rated Unified Parkinson’s Disease Rating
Scale (UPDRS) and patient-rated quality of life), and thus pro-
vides the most reliable summary available of the current published
evidence.
Physiotherapy intervention versus no-physiotherapy
intervention
This review provides evidence on the short-term (< three months)
benefit of physiotherapy in the treatment of PD. All outcomes
showed an improvement with physiotherapy intervention com-
pared with no intervention (except the 10- or 20-metre walk test).
However, significant benefit following physiotherapy intervention
was only observed for the gait outcomes of velocity, the two- or
six-minute walk test and step length; the functional and mobility
outcomes of the Timed Up &Go test, Functional Reach Test and
Berg Balance Scale, and clinician-rated UPDRS. It is of interest
that the direction of the treatment effect favoured physiotherapy
intervention in all, except one, outcome measure. The absence of
evidence in these outcomes is not necessarily evidence of absence
of a benefit for physiotherapy. One possible reason for this may
be the lack of data. Over 1500 participants were randomised into
the 33 trials included in this review, with 24 trials and 1234 par-
ticipants (81% of total) providing data for analysis. However, the
most data were provided for analysis of the outcome velocity, and
this included just 11 trials and 629 participants (51% of partici-
pants providing data).
Gait
People with PD frequently have problems with gait, and treatment
is usually targeted, maximising exercise tolerance, improving gait
pattern, maintaining or increasing independence regarding mo-
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bility and reducing the risk of falls. The most significant improve-
ment among the outcomes assessing gait was in velocity. In light
of previous experimental evidence, it may be hypothesised that the
improvement in velocity is linked to an increase in step or stride
length, or both, and that this in turn leads to a compensatory
decrease in cadence (Morris 1994; Morris 1996). In this review,
although a significant improvement in velocity was observed, we
found only a borderline improvement in step length, and no dif-
ference in stride length or cadence. This could again be due to a
lack of data, as a smaller number of studies reported step and stride
length and cadence (up to six studies) compared with velocity (11
studies). Thus, further data on the possible link between velocity,
cadence, step and stride length are required.
Freezing of gait is a prevalent motor disturbance within PD, and
is known to have a detrimental impact on quality of life, as well as
gait and mobility (Moore 2007). We found no difference in scores
derived from the Freezing of Gait Questionnaire, but this was only
measured in three trials (246 participants), again highlighting the
need for further data on this important area.
The observed differences in the three significant gait outcomes
(velocity, the two- or six-minute walk test and step length) were
relatively small. Therefore, their relevance and benefit to PD pa-
tients must be put into context in terms of what is considered
a minimally clinically important change (MCIC). Velocity was
significantly improved with physiotherapy intervention by 0.05
metres/second. Data on what is considered a MCIC are lacking
for PD patients, but some data have been reported in stroke pa-
tients. In one study, it was reported that an increase in velocity
of just 0.03 and 0.13 metres/second could translate into a change
from a limited household to an unlimited household walker and
an unlimited household to a most-limited community walker re-
spectively (Perry 1995). Our data fit in with the findings reported
by Perry (Perry 1995). For the two- or six-minute walk test and
step length, those participants who received physiotherapy inter-
vention were able to walk further over two or six minutes (by 16
m) and step length was increased by 3 cm. There is a lack of data
on the MCIC for these outcomes, but whilst a 16 m increase in
distance walked would probably be considered clinically impor-
tant, the importance of a 3 cm increase in step length is less clear.
Functional Mobility and Balance
The changes in functional mobility and balance within PD have
been well-documented (Bloem 2001). Of the functional mobil-
ity and balance outcomes assessed within this review, significant
improvements were observed in the Timed Up & Go test, Func-
tional Reach Test and Berg Balance Scale. The time taken to com-
plete the Timed Up & Go test was significantly improved by 0.61
seconds with physiotherapy. Despite this significant change, the
MCIC in PD patients is thought to be 11 seconds (Steffen 2008).
Therefore, the small change observed within this review may not
translate into a noticeable improvement within a person’s func-
tional mobility.
A five-point change is theMCICon theBergBalance Scale (Steffen
2008). In this review, there was a significant three-point improve-
ment in the Berg Balance Scale after physiotherapy intervention.
Although this is less than the five-point MCIC, the results are ap-
proaching the level of clinical importance (upper confidence in-
terval: 4.81). A significant improvement of 2 cm was also noted
in the Functional Reach Test, but this is somewhat lower than the
MCIC of 9 cm and 7 cm for forward and backward Functional
Reach Test (Steffen 2008).
Falls
Falls are a common and disabling problem within PD (Bloem
2001), with a high clinical impact and serious cost implications
to society. They are also a recurrent problem, with up to 51% of
those falling reporting two or more falls per year (Wood 2002).
Fear of falling has been recognised as a contributing factor to re-
current falls (Mak 2009). Within this review, fear of falling has
been captured through the Falls Efficacy Scale (standard and in-
ternational). No difference between treatment arms was observed
for this outcome. This might be attributed to the small number of
trials (and therefore participants) included within these analyses,
but could also indicate that an improvement in balance does not
automatically result in increased confidence in an individual’s abil-
ity not to fall. In turn, it could be hypothesised that an improve-
ment in balance does not directly equate to improved levels of mo-
bility and independence. Although fear of falling was not reduced
with physiotherapy within this review, it would be of interest to
assess whether the number of falls was reduced, as this may be
more relevant to patients. Unfortunately data on this were poorly
reported and measured too variably within the trials, and could
not be meta-analysed. However, in the seven trials where data on
the number of falls were reported, there was a general trend for a
reduction in the number of falls with physiotherapy intervention,
but there was no difference between the two treatment arms.
Clinician-Rated Disability
Significant improvements following physiotherapy intervention
were also observed for the clinician-rated UPDRS (total, ADL
and motor scores). The UPDRS total score was improved by 4.5
points, the ADL score by 1.4 points andmotor score by 4.1 points.
The MCIC for the UPDRS was reported in two studies. One
analysed data from two independent randomised controlled tri-
als and concluded the MCIC to be eight points for the UPDRS
total score, between two and three points for the ADL score and
five points for the motor score (Schrag 2006). The second study
performed a cross-sectional analysis on the 653 participants with
PD, and reportedMCIC of 2.3 to 2.7 points for motor and 4.1 to
4.5 points for total UPDRS (Shulman 2010). Taking into account
the recommendations of both Schrag (Schrag 2006) and Shulman
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et al (Shulman 2010), it can be concluded that the significant
improvements observed within this review are approaching or are
MCICs (theMCICs for the UPDRS total, ADL and motor scores
lie within the confidence interval). This suggests that physiother-
apy intervention is beneficial in improving motor symptoms and
may positively impact on ADL.
Patient-Rated Quality of Life
There was no significant benefit of physiotherapy intervention on
overall patient-rated quality of life (measured using the Parkin-
son’s Disease Questionnaire (PDQ)-39 Summary Index) or the
mobility domain of the PDQ-39, which is surprising considering
the significant improvements seen in the UPDRS scores. Another
study (Chandler 1999) assessed patient quality of life using the
generic Short Form-36 and also showed no effect of physiotherapy
intervention.
Comparison of Different Physiotherapy Interventions
Whilst, we found short-term benefit for physiotherapy interven-
tion in the treatment of PD, what is less clear is whether there is
a certain type of physiotherapy intervention which may provide
greater benefit. This would be of interest to both clinicians and
patients, so that appropriate physiotherapy interventions which
provide greater benefit can be delivered to patients with PD. To
assess this, we categorised the various physiotherapy interventions
used in the trials included in this review according to the type of
treatment administered and then compared using tests for hetero-
geneity. We found no evidence of any differences in the treatment
effect between the different physiotherapy interventions used for
any of the outcomes assessed. However, these were based on in-
direct comparisons (with limited data within each physiotherapy
intervention) so should be interpreted with caution, and would
be better assessed in trials directly comparing different types of
physiotherapy interventions.
This lack of difference between the different types of physiother-
apy intervention is perhaps not surprising. The content and de-
livery of the interventions used in the trials included within this
review are diverse in nature and, although attempts were made to
compare trials “like for like” through the creation of different cate-
gories, the interventions delivered varied substantially within these
categories. The variety in the therapy delivered is perhaps unsur-
prising. By nature physiotherapists are autonomous professionals
with differing sets of skills who work within their own scope of
practice (Chartered Society of Physiotherapy), and so this variation
in the interventions delivered within clinical trials may actually
reflect clinical practice. Secondly, and perhaps more importantly,
PD is recognised as a complex condition with an individualised
presentation (Van der Marck 2009). For this reason, Morris et al
(Morris 2010) recognises the importance of the physiotherapist
understanding the specific experience of PD in each patient, and
advocates that treatment is tailored to fit the individual’s com-
plaints, their lifestyle and personal interests, as opposed to a “one
size fits all” approach. Over the past decade, steps have been taken
to try and provide best practice consensus in the form of theDutch
KNGF guidelines for physical therapy in patients with Parkinson’s
disease (Keus 2004). However, this publication provides a guid-
ance framework rather than a “recipe” for treatment. It is therefore
important that physiotherapy interventions are compared against
each other within rigorous trial designs to determine which are
most effective. This will provide therapists with a menu of treat-
ment strategies, which are known to be effective, from which they
can devise individualised interventions.
Quality of the evidence
There has been an improvement in the trialmethodological quality
and reporting since the last Cochrane review (Deane 2001a) The
use of more robust randomisation methods, blinding and inten-
tion-to-treat analyses had increased since the previous review, al-
though are still inadequate. Of the 33 trials, only 14 trials provided
information on the randomisation method (of which nine were
considered low risk) and only five used a central randomisation
procedure to ensure concealment of treatment allocation. Twenty-
one used blinded assessors and eight used intention-to-treat anal-
ysis. The lack of information on this in many trial reports may not
necessarily indicate lack of implementation within the trial, but
without this information the level of bias within the individual
trials is difficult to assess. The need for further improvement in
the methodological quality of trials in physiotherapy for PD was
noted in another recent systematic review (Kwakkel 2007). Fu-
ture trials need to ensure that their designs fulfil the requirements
of a methodologically sound, large randomised controlled trial,
and that the reporting follows the CONSORT guidelines (Schulz
2010).
The trials included in the review were relatively small, with the
majority assessing the effect of physiotherapy intervention versus
no physiotherapy intervention over a short period of time with
limited follow-up. The overall size of trials has increased (with an
average of 50 participants per trial in this review compared to 25 in
the previous review), but the number of small and underpowered
trials remains a problem. Small trials may be subject to ‘random
error’ (Doll 1980), and consequently may give rise to false negative
or positive results. To highlight this point, this review illustrates
that any differences observed in the various outcome measures
showing benefit for physiotherapy were quite small. So trials need
to be large enough to detect these small but possibly clinically
important differences.
Further, it must be noted that only 11 of the 33 trials discussed
participant compliance. This is surprising as compliance can be an
important determinant of the outcomes measured in trials. There-
fore, it would be beneficial if the level of compliance is measured
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in future trials.
Another limitation is that the follow-up period in the trials in-
cluded in this review was relatively short. Outcome measures were
assessed by all trials at baseline and immediately or shortly after in-
tervention had ceased (one or two weeks with one trial (Goodwin
2009) assessing at 10 weeks post intervention). Thus, this review
is only able to provide conclusions on the short-term benefits of
physiotherapy. It is also important to consider results alongside
the possibility of a so-called honeymoon effect (Goetz 2008) in
the period during or just after physiotherapy, which may inflate
the treatment effect in favour of physiotherapy. Parkinson’s disease
is a long-term neurodegenerative disease, so it is important that
the long-term effect of treatment be assessed. Only eight of the 33
trials followed up participants and reported further data during
the post-treatment period (but this could have been only one week
or up to six months after the treatment period). The previous re-
view’s recommendations were for participants to be followed up
for at least six months; but only one trial (Schmitz-Hubsch 2006)
reported follow-up data at six months post treatment completion.
Long-term data will provide valuable information about the du-
ration of any improvement following therapy.
The outcomemeasures included in this reviewwere standard phys-
iotherapy and PD outcomes. However, PD is a multidimensional
disease, and many important outcomes were either poorly or not
reported, this includes data on the number of the falls, depression
and anxiety, adverse events and the health of the carer support-
ing the person with PD. Further, no health economics analysis of
physiotherapy intervention was reported, therefore, little is known
about the cost-effectiveness and economic value of this therapy.
Future trials should include these outcomes.
In summary, this review provides evidence on the short-term (<
three months) benefit of physiotherapy intervention for the treat-
ment of PD. Importantly, although most of the observed differ-
ences between the two treatments were small, the improvements
seen for velocity, Berg Balance Scale, and UPDRS scores were at
levels considered to be of clinical importance. To clarify the long-
term (if any) benefit of physiotherapy, further large, well-designed
randomised trials with a follow-up of at least 12 months which
assess the impact of this treatment on all aspects of a patients PD,
alongside a health economics assessment, are needed.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Physiotherapy provides short-term benefit in the treatment of PD.
There were significant benefits with physiotherapy intervention
for the following outcomes: two- or six-minute walk test, velocity,
step length, Timed Up & Go test, Functional Reach Test, Berg
Balance Scale, UPDRS total, ADL and motor scores. Although
most of the observed differences between the two treatment arms
were small, the improvements seen for velocity, Berg Balance Scale
and UPDRS scores were at levels considered to be of clinical im-
portance.
The long-term, if any, benefit of physiotherapy remains unan-
swered, as does which type of physiotherapy intervention to de-
liver. Therefore, although this review has provided evidence that
physiotherapy intervention may be of benefit to patients with PD,
it has also highlighted that further evidence is needed before firm
conclusions can bemade on the long-termbenefit andwhich phys-
iotherapy intervention to use.
Implications for research
Themajority of the studies in this reviewwere small andhad a short
follow-up period. It is clear that larger randomised controlled trials
are required, particularly focusing on improving trial methodol-
ogy and reporting. Rigorous methods of randomisation should be
used and the allocation adequately concealed.Data should be anal-
ysed according to intention-to-treat principles and trials should
be reported according to the guidelines set out in the CONSORT
statement (Schulz 2010).
There were also a large variety of outcome measures assessed in
the trials, but there were only enough data for meta-analysis to
be performed for eighteen outcomes. This review illustrates the
need for the universal employment of relevant, reliable and sen-
sitive outcome measures. Additionally, only one trial looked at
the longer-term benefit of physiotherapy intervention. In order to
assess whether, or how long, any improvements due to physiother-
apy intervention may last, it is important that long-term follow-
up is performed.
There was no evidence to indicate the best form of physiotherapy
intervention. The comparisons of the different physiotherapy in-
terventions in this review were based on indirect comparisons be-
tween the individual trials. A more reliable comparison would be
obtained in large randomised trials that directly compare different
physiotherapy interventions.
This review highlights the variety of physiotherapy interventions
being used in the treatment of PD. There is a need for more
specific trials with improved treatment strategies to underpin the
most appropriate choice of physiotherapy intervention and the
outcomes measured.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Allen 2010
Methods Parallel-group design.
Randomised using a randomisation schedule with randomly permuted block sizes, developed by an
investigator not involved in participant recruitment or assessment
Data analysed on an intention-to-treat basis.
Treated as outpatients and at home for 48-72 hours over 6 months
Assessed at baseline and post-intervention.
Assessors were blinded.
Participants 24 participants in the exercise group and 24 in the control group. 3 drop-outs in the exercise group
Participants’ mean age 66 years (exercise), 68 years (control); male/female 13/11 (exercise), 13/11
(control); duration of PD 7 years (exercise), 9 years (control). Hoehn and Yahr stage not reported
Inclusion criteria:Diagnosis of idiopathic PD, able towalk independently (with orwithout an aid), fallen
in the last year or deemed tobe at risk of falling, 30-80 years in age, on the samePDmedication for the last
2 weeks. Exclusion criteria: significant cognitive impairment (MMSE < 24), had another neurological/
musculoskeletal/cardiopulmonary/metabolic condition that would interfere with safe conduct of the
training or testing protocol
Interventions Exercise: 40-60 min program of progressive lower limb strengthening and balance exercises (targeted
leg muscle strength, balance and freezing). Once monthly exercise classes with the remaining exercise
sessions at home
Control: Usual care with advice on fall prevention and falls diary recording any fall
Drug therapy was allowed to vary.
Outcomes PD falls risk score.
Knee extensor strength.
Co-ordinated stability.
Sway.
Maximum balance range in standing.
Alternate step test.
Freezing of Gait Questionnaire.
Sit to stand time.
Fast walking speed.
Comfortable walking speed.
Short physical performance battery.
Falls Efficicacy Scale - International.
PDQ-39.
Participants were assessed in their home about 1 hour after taking their usual PDmedication, the order
of measurements was standardised
Notes Participants in the exercise group who experienced freezing of gait were also instructed in cueing
strategies to reduce freezing as part of their exercise program
Exercise group completed a mean of 70% of total prescribed exercise sessions
Risk of bias
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Allen 2010 (Continued)
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Low risk Randomly permuted block size.
Concealment of Allocation Unclear risk No information provided.
Similarity at Baseline Low risk
Intention-to-Treat Analysis Low risk An intention-to-treat approach was used for all
analyses.
Withdrawals Describe Low risk 6% overall, but all from exercise group.
Cointerventions Constant Unclear risk Allowed variation in levodopa therapy.
Credible Placebo Low risk Falls prevention advice given in both arms.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Ashburn 2007
Methods Parallel-group design.
Stratified by NHS using blocks of size four. Random allocation by telephoning the medical statistics
group at University of Southampton. Participants were informed of their allocation by telephone
Data analysed on an intention-to-treat basis.
Treated as outpatients 7 times a week for a 6-week period, for a total period of 42 hours
Assessed at baseline, 8 weeks and 6 months.
Participants 70 participants in the exercise group and 72 in the control group. 6 drop-outs in the exercise group
and 8 in the control group
Participants’ mean age 72.7 years (exercise), 71.6 years (control); male/female 38/32 (exercise), 48/24
(control); Hoehn and Yahr stage 3.14 (exercise), 3.11 (control); duration of PD 7.7 years (exercise), 9
years (control)
Inclusion criteria: confirmed diagnosis of PD, independently mobile, living at home in the community,
experienced more than one fall in the previous 12 months, passed a screening for gross cognitive
impairment (Mini Mental State). Exclusion criteria: unable to participate in assessments because of
pain, acute medical condition, in receipt of or soon to receive treatment
Interventions Exercise: personalised home-based exercise and strategy programme. Following assessment, treatment
goals were established with participants and exercises from the exercise menu were taught. Participants
were visited weekly at home by physiotherapist for approximately 1 hour. 6 levels of exercise progression
which comprised of muscle strengthening, range of movement, balance training and walking. Strategies
of falls prevention and movement initiation and compensation taught by physiotherapist. Participants
were asked to complete the exercises daily for max of 1 hour and to keep record. Phoned monthly to
encourage exercises
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Ashburn 2007 (Continued)
Control: Usual care, contact with local PD nurse.
Drug therapy was not described.
Outcomes Self-reported falls diary.
Functional reach.
Timed up and go test.
Chair stand test.
Berg balance test.
Euroqol-5d, QoL thermometer.
Self-assessment Parkinson’s disease disability scale.
Tests were carried out mid-way between drug doses.
Notes At 6 months 34% in the control group were participating in extra rehabilitation compared with 25%
in the exercise group
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Low risk Block randomisation (block size 4)
Concealment of Allocation Low risk Telephone call to central office
Similarity at Baseline Low risk
Intention-to-Treat Analysis Low risk Analysis was on an intention-to-treat basis.
Withdrawals Describe Low risk 6% at 8 weeks and 8% at 6 months.
Cointerventions Constant Unclear risk Drug therapy was not described.
Credible Placebo Low risk Controls had contact with PD nurse.
Blinded Assessors Unclear risk Assessor remained blinded to group allocation but
reported being aware of the allocation of 18 exer-
cise and 11 control participants at 8 weeks and 25
exercise and 14 control participants at 6 months
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Cakit 2007
Methods Parallel-group design.
Method of randomisation not stated.
Method of analysis not described.
Treated as outpatients for an unspecified time over 8 weeks (30 minute sessions)
Assessed at baseline and immediately after treatment.
Assessors were blinded.
Participants 27 participants in the treadmill group and 27 in the control group. 6 drop-outs in the treadmill group,
17 drop-outs in the control group
No baseline characteristics given for drop-outs. Participants’ mean age 71.8 years; male/female 16/15.
The Hoehn and Yahr scores were not given. The mean duration of PD was 5.6 years
Inclusion criteria: Patientswith PDwho fulfilled theUKParkinson’sDisease SocietyBrainBankCriteria,
medically stable, able to walk 10 metre distance at least 3 times with or without assistive device, able
to provide informed consent. Exclusion criteria: participants who had neurological conditions other
than idiopathic PD, scored greater than 3 in Hoehn and Yahr, scored less that 20 in MMSE, postural
hypotension, cardiovascular disorders, class C or D exercise risk by the American College of Sports
Medicine (ACSM) criteria, musculoskeletal disorders, visual disturbance or vestibular dysfunction
limiting locomotion or balance
Interventions Treadmill: 8 week exercise program using incremental speed-dependent treadmill training. Programme
comprised of stretching, range of motion exercise and treadmill training. The treadmill session lasted for
30min and participants were observed during treadmill training by a physiatrist, who gave no assistance
in the actual performance of the movements. Maximum tolerated walking speed was determined before
the training session. This speed was then halved and used for a 5 min warm-up period. After the warm-
up period the belt speed was increased by increments of 0.6 km/h every 5 min. When the belt speed was
increased to the highest speed at which the participant could walk safely and without stumbling, this
maximum-achieved belt speed was maintained for 5 min and then followed by 0.6 km/h decrements.
The participant maintained the rest of the treadmill session with this speed for 15 min
Control: no intervention.
Drug therapy was constant during the trial.
Outcomes Berg Balance Test.
Dynamic Gait Index.
Falls Efficacy Scale.
Walking distance on treadmill.
Tolerated maximum speed on treadmill (km/h).
Examinations took place when participants were in the ’on’ phase of medication
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Method of randomisation not stated.
Concealment of Allocation Unclear risk Method of randomisation not stated.
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Cakit 2007 (Continued)
Similarity at Baseline Unclear risk Baseline data given overall, not split by treatment
group.
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe High risk 43% withdrawals.
Cointerventions Constant Low risk Drug therapy was constant during the trial.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Canning 2008
Methods Parallel-group design.
Randomisation method not stated.
Method of analysis not described.
Treated at home 3 times a week for 6 weeks, for a total of 9-12 hours
Assessed at baseline, 7 and 13 weeks.
Assessors were blinded.
Participants 10 participants in the treadmill group and 10 participants in the control group. Drop-outs 2 (treadmill)
, not stated (control)
Mean age of all the participants, 61 years.
Inclusion criteria: clinical diagnosis of idiopathic PD, aged 30-80 years, subjective disturbance of gait
and/or a UPDRS gait sub score of 1, sedentary, defined as performing less than 2 hours / week of
leisure-time physical activity over the prior 3 months, have adapted to their current anti-Parkinsonian
medication for at least 2 weeks, be cognitively-intact, have no freezing ’on’ medication, Hoehn and
Yahr stage 1 or 2. Exclusion criteria: motor fluctuations or dyskinesias which are disabling, require the
use of a walking aid, more than one fall in the last 12 months, MMSE score of < 24, exhibit other
neurological or musculoskeletal conditions affecting walking, chest pain at rest or during exercise in
the last 3 months, or heart attack, angioplasty or heart surgery in the last 6 months
Interventions Treadmill: Walked on the treadmill holding onto the handle bars for 30-40 minutes
Control: Advised to maintain current activity levels.
Drug therapy was not described.
Outcomes 6-minute walk test to assess walking capacity.
UPDRS - motor examination.
PDQ-39 to assess quality of life.
Walking automaticity, velocity of walking 10m while performing a concurrent (cognitive or cognitive +
physical) task as expressed as a percentage of the walking velocity of walking 10 m without performing
the concurrent task
Walking consistency determined as the co-efficients of variation for stride time and stride length recorded
during the 6-minute walk test
7-pt Likert scale to assess fatigue.
Examinations took place during ’on’ periods.
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Canning 2008 (Continued)
Notes Seven of the 24 exercise sessions were supervised by a physiotherapist
Abstract only, extra data from ClinicalTrials.gov
No means and SDs available.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Method of randomisation not stated.
Concealment of Allocation Unclear risk Concealed allocation stated in abstract.
Similarity at Baseline Unclear risk Only information given was mean age of all par-
ticipants was 61 years
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe High risk 20% drop-out/withdrawal.
Cointerventions Constant Unclear risk Drug therapy was not described.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Cerri 1994
Methods Parallel-group design.
Randomisation method was not stated.
Method of analysis not described.
Treated as outpatients for 15 hours over 3 weeks followed by a home exercise program for 2 months
then the cycle was repeated. (Total of 30 hours therapy)
Assessed at baseline and immediately after treatment.
Not stated whether assessors were blinded.
Participants 3 participants in the exercise group and 3 in the control group. Drop-outs not described
Participants’ were all aged between 58-68 years and Hoehn and Yahr stage 3 and 4. No data were given
for the sex of the participants
Inclusion criteria: PD, stage 3 and 4 of Hoehn and Yahr scale, treated with L-dopa for more than 4
years with incomplete control of rigidity and tremor. No exclusion criteria stated
Interventions Exercise: Individual. Physical exercise program with neuromuscular facilitation techniques to improve
posture, inhibit rigidity and ’conscientize’ movements
Control: Untreated.
Drug therapy was allowed to vary during trial.
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Cerri 1994 (Continued)
Outcomes Webster disability Scale.
Activity of daily living.
L-dopa reduction.
Not stated when examinations took place.
Notes Abstract only.
No means and SDs available.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Unclear risk Only information given was that all participants
were aged between 58-68 years and Hoehn and
Yahr stage 3 and 4
Withdrawals Describe Unclear risk Drop-outs not described.
Cointerventions Constant Unclear risk 2 participants in the intervention group reduced
dose of L-dopa to avoid side-effects. Allowed vari-
ation in medication
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
Chandler 1999
Methods Parallel-group design.
Randomisation method was not stated.
Method of analysis not described.
Treated at home where they were assessed by a physiotherapist 5 times over a 12 month period. The
amount of physiotherapy was variable and depended upon the participant’s needs
Assessed at baseline and during the duration of the trial (at 3, 6, 9 and 12 months) (see Outcomes)
Assessors were not blinded.
Participants 32 participants in the physiotherapy group and 35 in the control group. Drop-outs 6 (physiotherapy),
9 (control)
Participants’ mean age 65 years (physiotherapy), 66 years (control). 31 males and 21 females completed
the study; Hoehn and Yahr for 47 of the participants, 2.6
Inclusion criteria: Idiopathic PD, not receiving physiotherapy, no access (including self-referral) to a
physiotherapy review system. No exclusion criteria stated
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Chandler 1999 (Continued)
Interventions Physiotherapy: Individualised, based on holistic approach in which empowerment of participants and
carers was a strong element. Aimed to enhance the performance of activities. Gait and balance exercises
using verbal, auditory and visual cues. Exercises to reduce stiffness, improve muscle tone and increase
trunk rotation. Advice on transfers. Education in use of walking aids, reorganisation of environment to
reduce hazards and facilitate movement. Leisure pursuits and social contacts encouraged after strategies
were adopted to facilitate these. Relaxation techniques (audio tapes and aromatherapy) to improve sleep
patterns. Aimed to reduce pain with education in postural awareness, exercise, TENS and acupuncture.
Referral to other health professionals and social services for aids and appliances.
Control: Untreated.
Drug therapy could vary.
Outcomes Functional Independence Measure*.
Nottingham extended Activities Daily Living*.
UPDRS - motor subsection*.
Timed walk*.
9 hole peg test*.
SF-36 +.
PDQ-39 +.
* Baseline, 3, 6, 9, 12 months.
+ Baseline, 6, 12 months.
Not stated when during day examinations took place.
Notes Participants referred to other health professionals and social services during trial
Occupational therapy component to the physiotherapy.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Unclear risk Only gave information for age split by treatment
group.
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe High risk 22% withdrawals.
Cointerventions Constant Unclear risk Drug therapy could vary.
Blinded Assessors High risk Assessors were not blinded.
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de Bruin 2010a
Methods Parallel-group design.
Method of randomisation not stated.
Method of analysis not described.
Treated as outpatients 3 times per week for a 13 week period
Assessed at baseline and immediately after treatment.
Assessors were blinded.
Participants 16 participants in the cueing group and 17 participants in the control group. Drop-outs 4 (cueing), 3
(control)
Participants’ mean age 64.1 years (cueing), 67.0 years (control); male/female 6/5 (cueing), 5/6 (control);
Hoehn and Yahr 2.3 (cueing), 2.1 (control); mean duration of PD 6.4 years (cueing), 4.5 years (control)
. No baseline characteristics were given for the drop-out
Inclusion criteria: Diagnosis of PD (United Kingdom Brain Bank Criteria), Hoehn and Yahr stage
II-III, stable medication regimen, independently mobile without the use of a walking aid, and intact
hearing. Exclusion criteria: diagnosis of less than 1 year, undergone deep brain stimulation surgery,
experience regular freezing episodes, unable to ambulate independently in the community, presence of
neurological disorders or co morbidities likely to affect gait, scoring 24 or less on the MMSE and/or
already listening to music
Interventions Cueing: Walking at a self-selected pace for 30 min, 3 times per week whilst listening to a preloaded
music battery on an MP3 player. The music battery was individualised for each participant matching
music preferences and the cadence of their preferred walking speed
Control: Continued with their regular activities.
Drug therapy was not described.
Outcomes Velocity.
Stride time.
Stride length.
Cadence.
Stride time variability.
UPDRS (III) score.
Examined on medications at the same time of day.
Notes Compliance in the intervention group was good. 2 participants in the music group took a 1 week break
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Low risk
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
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de Bruin 2010a (Continued)
Withdrawals Describe High risk 21% withdrawals.
Cointerventions Constant Unclear risk Drug therapy was not described.
Blinded Assessors Low risk UPDRS evaluator was blinded to participant
group assignment.
de Bruin 2010b
Methods Parallel-group design.
Method of randomisation was not stated.
Method of analysis not described.
Treated as outpatient 3 times per week for 13 weeks.
Assessed at baseline and post-intervention.
Not stated whether assessors were blinded.
Participants 8 participants in the cueing group and 5 participants in the control group. No drop-outs described
No baseline characteristics reported.
Inclusion criteria: PD. No exclusion criteria.
Interventions Cueing: Walking 3 times per week whilst listening to an individual music playlist. Playlists closely
matched each individual’s music preferences and preferred cadence
Control: Continued with their regular activities.
Drug therapy was not described.
Outcomes Spatiotemporal parameters approach, crossing and recovery steps of obstacle crossing were evaluated
using a GAITRite mat
Step velocity.
Step length.
Not stated when during the day examinations took place.
Notes Abstract, only P values reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Unclear risk No baseline characteristics reported.
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe Unclear risk No drop-outs described.
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de Bruin 2010b (Continued)
Cointerventions Constant Unclear risk Drug therapy was not described.
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
Earhart 2010
Methods Parallel-group design.
Method of randomisation was not stated.
Method of analysis not described.
Treated as outpatients for 24 hours over 3 months.
Assessed at baseline and post-intervention.
Assessor was blinded.
Participants Total of 62 participants randomised. 26 participants in the dance group and 26 participants in the
control group were analysed. 10 drop-outs
Total participants mean age 70.3 years, mean Hoehn and Yahr stage 2.5, male/female ratio 35/27
Inclusion criteria: Idiopathic PD. No exclusion criteria.
Interventions Dance: Tango class for 1 hour, twice weekly.
Control: No exercise.
Drug therapy was not described.
Outcomes MDS-UPDRS.
Participants were assessed while off medication (12-hr withdrawal)
Notes Abstract - limited data. Author contacted who provided n numbers and drop-out data
Risk of bias
Bias Authors’ judgement Support for judgement
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Unclear risk Baseline data not split by treatment group.
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe High risk 16% withdrawals.
Cointerventions Constant Unclear risk Drug therapy was not described.
Blinded Assessors Low risk Assessor was blinded to group allocation.
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Ellis 2005
Methods Cross-over design.
Block randomisation procedure was used in which each sealed envelope contained four Group A
assignments and four Group B assignments. This process continued until a total of 68 participants
were randomly allocated
Method of analysis not described.
Treated as outpatients 2 times a week for 6 weeks for a total of 18 hours (1.5 hour sessions)
Assessed at baseline, immediately after 1st treatment. Immediately before 2nd treatment and 3 months
after 2nd treatment
Assessors were blinded.
Participants 35 participants in the physiotherapy group and 33 in the control group. 11 drop-outs
Participants’ mean age 64 years (physiotherapy), 63 years (control), male/female ratio, 25/10 (physio-
therapy), 26/7 (placebo). Mean Hoehn and Yahr 2.5 (physiotherapy), 2.4 (control)
Inclusion criteria: Stable medication usage, Hoehn and Yahr stage 2 or 3, at least 1 score of 2 or
more for at least 1 limb for either the tremor, rigidity or bradykinesia item of the UPDRS, ability to
walk independently, age 35-75 years, no severe cognitive impairment (MMSE
>
= 24), no other severe
neurologic, cardiopulmonary or orthopaedic disorders, not having participated in a physical therapy
or rehabilitation program in the previous 2 months. No exclusion criteria stated
Interventions Physiotherapy: 1.5 hour long physical therapy session consisting of stretching, functional training, gait
training, auditory cueing, balance, recreational, relaxation
Control: Medical therapy only.
It was not stated whether drug therapy was kept constant during the trial
Outcomes Sickness Impact Profile (SIP-68).
UPDRS (Sections I, II, III).
Comfortable walking speed.
Assessments were performed at the same time of day and in the same order. Assessments were performed
in the ’on’ state for participants who experience motor fluctuations
Notes Of the 68 participants, 50 attended all treatment sessions.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Low risk Blocked randomisation (block size 8) with sealed
envelopes.
Concealment of Allocation High risk Sealed envelopes which contained 8 group alloca-
tions (4 per group)
Similarity at Baseline Low risk
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe High risk 16% at the end of the trial.
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Ellis 2005 (Continued)
Cointerventions Constant Unclear risk It was not stated whether drug therapy was kept
constant during the trial
Blinded Assessors Low risk Assessors were blinded to group allocation.
Fisher 2008
Methods Parallel-group design.
Randomisation was done by the participants with their eyes closed; they selected a card corresponding
to one of the 3 groups
Method of analysis not described.
Treated as outpatients for 24 sessions over 8 weeks for both treatment arms, 6 sessions over 8 weeks for
control group
Assessed at baseline and immediately post treatment.
Assessors were blinded.
Participants 10 participants in the Treadmill group, 10 participants in the physiotherapy group and 10 participants
in the control arm. No drop-outs described
Participants’ mean age, 64.1 years (treadmill), 61.5 years (physiotherapy), 63.1 years (control). Male/
female ratio, 6/4 (treadmill), 5/5 (physiotherapy), 8/2 (control). Mean Hoehn and Yahr 1.9 in all 3
groups. Mean duration of PD 1.2 years (treadmill), 0.7 years (physiotherapy), 1.5 years (control)
Inclusion criteria: Early stage PD, diagnosis of PDwithin 3 years of study participation,Hoehn andYahr
stage 1 or 2, 18 years or older, medical clearance from primary care physician to participate in exercise
programme, ability to walk. Exclusion criteria: Medical or physical screening examination showed a
score of less than 24 on the MMSE, there were physician determined major medical problems such
as cardiac dysfunction that would interfere with participation, they had musculoskeletal impairments
or excessive pain in any joint that could limit participation in an exercise programme, had insufficient
endurance and stamina to participate in exercise 3 times per week for a 1 hour session
Interventions Treadmill: Level of intensity was defined by MET. High intensity exercise greater than 3 METs. Body
weight supported (BWS) treadmill training. Goal of each session was to reach and maintain a MET
> 3. Exercise progressed by decreasing BWS (initially 10% of participants’ bodyweight) and physical
assistance, increasing the treadmill speed and time on the treadmill, with the end goal for each participant
to walk on the treadmill continuously for 45 min within the MET range
Physiotherapy: Less than 3 METs. This group was representative of general or traditional physical
therapy. Each 45 min session was individualised and consisted of activities from 6 categories 1) passive
range of motion and stretching 2) active range of motion 3) balance activities 4) gait 5) resistance
training 6) practice of functional activities and transitional movements
Control: Zero intensity group. Six 1 hour education classes taken over an 8 week period
Drug therapy was constant during the trial.
Outcomes UPDRS (Total, I, II and III subscores).
Hoehn and Yahr.
Functional assessments.
Walking test.
Sit-to-stand test.
Transcranial magnetic stimulation.
All participants took their customary medications at the same time relative to each assessment
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Fisher 2008 (Continued)
Notes Participants were allowed to continue their customary exercise routines and filled out a daily exercise
diary
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method High risk Participants self-selected a card with eyes closed.
Concealment of Allocation High risk Participants self-selected a card with eyes closed.
Similarity at Baseline Low risk
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe Unclear risk No drop-outs described.
Cointerventions Constant Low risk All medication kept stable during course of study.
Credible Placebo Low risk Education classes attended by controls.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Ganesan 2010
Methods Parallel-group design.
Method of randomisation not stated.
Method of analysis not described.
Treated as outpatients for 8 hours over 4 weeks.
Assessed at baseline, at 2 and 4 weeks.
Not stated if assessors were blinded.
Participants Total of 20 participants.
No baseline characteristics were reported.
Inclusion criteria: idiopathic PD, stable doses of dopaminomimetic drugs. No exclusion criteria
Interventions Treadmill: Partial weight supported treadmill gait training with 20% unweighted for 30 min per day,
4 times per week
Control: Did not receive any specific intervention.
Drugs were stable at time of randomisation.
Outcomes UPDRS.
Dynamic Posturography.
Berg Balance Scale.
Tinetti performance orientated mobility assessment.
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Ganesan 2010 (Continued)
Tinetti balance score.
Gait score.
Participants were assessed in best ’ON’ state.
Notes Abstract - only P values reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Unclear risk No baseline characteristics were reported.
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe Unclear risk No information provided (abstract only).
Cointerventions Constant Unclear risk Only information provided was that drugs were
stable at time of randomisation
Blinded Assessors Unclear risk Not stated if assessors were blinded.
Goodwin 2009
Methods Parallel-group design.
Telephone randomisation external to the research team with 1:1 allocation in geographical cohorts
Data were analysed on an intention-to-treat basis.
Treated as outpatients for an unspecified time over 10 weeks
Assessed at baseline and at 20 and 30 weeks.
Assessors were not blinded.
Participants 64 participants in the exercise group and 66 in the control group. 7 drop-outs in total
Participants’ mean age 72.0 years (exercise) 70.1 years (control). Male female ratio, 39/25 (exercise),
35/31 (control). Mean Hoehn and Yahr 2.6 (exercise), 2.4 (control). Mean duration of PD 9.1 years
(exercise), 8.2 years (control)
Inclusion criteria: Diagnosis of idiopathic PD (confirmed by specialist), self-reported history of 2 or
more falls in the past year, able to mobilise independently with/without a walking aid, resident in
Devon, willingness to be randomised and provide written informed consent. Exclusion criteria: needed
supervision or assistance from another person to mobilise indoors, significant co-morbidity that affect
ability or safety to exercise (e.g. unstable angina, unstable diabetes, significant postural hypotension,
severe pain, significant dyskinesia), were unable to follow verbal or written instructions in English
Interventions Exercise: 10 weeks of supervised group strength and balance training plus unsupervised home exercises
Control: Usual care.
Drug therapy could vary.
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Goodwin 2009 (Continued)
Outcomes Falls Incidence.
Number of fallers/recurrent faller.
Injuries.
Berg balance scale.
Timed Up and Go.
Fall Efficacy Scale - International.
EQ-5D.
Household and recreational physical activity (Phone-FITT).
Not stated when examinations took place.
Notes Abstract. Additional information and data obtained from author
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Telephone randomisation external to the research
team with 1:1 allocation in geographical cohorts
Concealment of Allocation Low risk Telephone randomisation external to the research
team with 1:1 allocation in geographical cohorts
Similarity at Baseline Low risk
Intention-to-Treat Analysis Low risk
Withdrawals Describe Low risk 5% withdrawals.
Cointerventions Constant Unclear risk Participants changed their medication as appropri-
ate as part of usual care
Credible Placebo Unclear risk Control group received usual care.
Blinded Assessors High risk Assessors were not blinded.
Hackney 2009
Methods Parallel-group design.
Randomisation was conducted by one author by selecting 1 of the 4 groups from a hat
Method of analysis not described.
Treated as outpatients for 20 hours within 13 weeks (1 hour sessions)
Assessed at baseline and within one week of completing 20 sessions
Assessors were blinded.
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Hackney 2009 (Continued)
Participants 19 participants in the tango group, 19 in the waltz/foxtrot group, 17 in the Tai Chi group and 20 in
the control group. 5, 2, 4 and 3 drop-outs from the tango, waltz/foxtrot, Tai Chi, and control group
respectively
Participants’ mean age, 68.2 years (tango), 66.8 years (waltz/foxtrot), 64.9 years (Tai Chi), 66.5 years
(control); male/female 11/3 (tango), 11/6 (waltz/foxtrot), 11/2 (Tai Chi), 12/5 (control). Mean Hoehn
andYahr 2.1 (tango), 2.0 (waltz/foxtrot), 2.0 (Tai Chi) and 2.2 (control).Mean duration of PD6.9 years
(tango), 9.2 years (waltz/foxtrot), 8.7 years (Tai Chi), 5.9 years (control). No baseline characteristics
were given for drop-outs
Inclusion criteria: Hoehn and Yahr stages 1-3, at least 40 years of age, could stand for at least 30 min,
walk independently 3 or more metres with or without assistive device, diagnosis of Idiopathic PD
using diagnostic criteria for clinically defined ’definite PD’ based upon published standards, participants
demonstrated clear benefit from levodopa, cognitively intact. Exclusion criteria: history of neurological
deficit other than PD, dementia, another measure of cognitive function and a separate part of the
study not reported where all participants were required to perform a subtraction task while walking (all
completed with 85% accuracy), considered cognitively intact
Interventions Dance: Experienced professional ballroom dancer taught progressive tango or waltz/foxtrot lessons for
1 hour twice weekly. Instructor equally versed in both dances attempted to give all students equal
attention. Both genders spent equal time leading and following dance roles. All steps done in closed
practice position where participants maintain contact through upper extremities and face one another
Martial arts: Received progressive lessons for 1 hour twice weekly on Tai Chi’s first and second circles
including 37 postures of the Yang Short Style of Cheng Manching from an experienced instructor
Control: No intervention.
Drug therapy was kept constant during the trial.
Outcomes PDQ-39.
UPDRS III.
Berg Balance Scale.
Timed Up and Go.
6-minute walk test.
Freezing of gait questionnaire.
Forward and backward gait.
Gait velocity.
Stride length.
Single support time.
Exit questionnaire.
Tandem Stance Test (TS).
One Leg Stance test (OLS).
Assessments took place at a standardised time when the participants were in the ’on’ state
Notes 1 participant was excluded from the study due to medication change. Participants were instructed not
to change their habitual exercise routines
Data taken from all three publications.
The tango and waltz/foxtrot arms assessed were suitably similar and were therefore combined to give
one comparison of dance
Risk of bias
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Hackney 2009 (Continued)
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method High risk Conducted by one author by selecting 1 of the 4
groups from a hat
Concealment of Allocation High risk Conducted by one author by selecting 1 of the 4
groups from a hat
Similarity at Baseline Low risk
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe High risk 19% withdrawals.
Cointerventions Constant Low risk Drug therapy was kept constant during the trial.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Homann 1998
Methods Parallel-group design.
Participant’s names were put into alphabetical order and then randomised using computer-generated
random number tables
Method of analysis not described.
Treated as outpatients for 14 ’units’ over 5 weeks.
Assessed at baseline and immediately after treatment.
Not stated whether assessors were blinded.
Participants 8 participants in physiotherapy group and 7 in placebo group. No drop-outs were described
No baseline characteristics available from abstract.
Inclusion criteria: Idiopathic PD according to UK Brain Bank diagnostic criteria. No exclusion criteria
Interventions Physiotherapy: Individual Bobath program focusing on proprioceptive skills to improve posture and
gait
Control: Untreated.
Drugs were stable for duration of therapy.
Outcomes UPDRS.
Axial symptoms.
Stride length.
Walk velocity.
Stride cadence.
Notes Abstract and poster only.
No numerical data available.
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Homann 1998 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Low risk Participant’s names were put into alphabetical or-
der and then randomised using computer-gener-
ated random number tables
Concealment of Allocation Low risk Based on information above, assumed treatment
allocation performed once all patients recruited
Similarity at Baseline Unclear risk No baseline characteristics available from abstract.
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe Unclear risk No drop-outs described.
Cointerventions Constant Low risk Drugs were stable for duration of therapy.
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
Keus 2007b
Methods Parallel-group design.
Randomised in blocks of four in order of enrolment. Independently assigned with concealed allocation
The data were analysed on an intention-to-treat analysis.
Treated as outpatients for an unspecified period of time, once or twice weekly for 10 weeks
Assessed at baseline and immediately after treatment.
Assessor was blinded.
Participants 14 participants in the physiotherapy group and 13 in the control group. 1 drop-out from the control
group
Participants’ median age, 65 years (physiotherapy), 71 years (control). Male female ratio, 11/3 (phys-
iotherapy), 11/2 (control). Mean Hoehn and Yahr 2.4 in both groups. Mean duration of PD 7 years
(physiotherapy), 6 years (control)
Inclusion criteria: Idiopathic PD according to the UK Parkinson’s Disease Society Brain Bank Criteria,
stable reaction to anti-Parkinsonian medication, at least one mobility-related activity limitation within
core areas of physiotherapy practice in PD (gait, balance, posture and transfers) experienced by the par-
ticipant as important. Exclusion criteria: Hoehn and Yahr stage 5 during the ’on’ period, physiotherapy
within 4 months prior to randomisation, severe co-morbidity influencing mobility or life threatening
(e.g. cancer), not motivated to participate in physiotherapy, severe cognitive impairment defined by a
MMSE score ≤ 24, presence of psychiatric impairments
Interventions Physiotherapy: Once or twice weekly individual physiotherapy sessions. Delivered by a physiotherapist
trained in the use of evidence based practice guidelines. Interventions included PD-specific techniques
such as cueing, cognitive movement strategies and general techniques such as training of balance, leg
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Keus 2007b (Continued)
strength and physical fitness. The intervention targeted balance, transfers, posture, gait, dependent on
the participant’s main complaint
Control: No physiotherapy.
It was not stated whether drug therapy was kept constant during the trial
Outcomes Patient preference outcome scale.
The Parkinson Activity Scale.
Mobility domain of the Dutch validated version of the PD questionnaire
Assessments took place during the participants subjectively best ’on’ phase
Notes Most participants received six to thirteen sessions of physiotherapy in the nine week period
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Low risk Block size of 4.
Concealment of Allocation Unclear risk Independently assigned with concealed allocation.
Similarity at Baseline Low risk
Intention-to-Treat Analysis Low risk Data were analysed according to the intention-to-
treat principles
Withdrawals Describe Low risk 1 drop-out from control group (4%)
Cointerventions Constant Unclear risk It was not stated whether drug therapy was kept
constant during the trial
Blinded Assessors Low risk Assessor was blinded to group allocation.
Klassen 2007
Methods Parallel-group design.
Randomisation method was not stated.
Method of analysis not described.
Treated as outpatients for 45 hours (exercise and education), 30 hours (exercise only) over 12 weeks
Assessed at baseline, immediately and 3 months after treatment
Assessors were blinded.
Participants 9 participants in the exercise and education group, 9 in the exercise group and 8 in the control group.
1 drop-out (exercise and education), 1 (exercise), 2 (control)
Median age 62 years (exercise and education), 70 years (exercise), 66.5 years (control). Male/female
ratio, 7/2 (exercise and education), 5/3 (exercise), 5/1 (control). Hoehn and Yahr 1.9 (exercise and
education), 1.4 (exercise), 1.5 (control).Years since diagnosis 4 years (exercise and education), 3 years
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Klassen 2007 (Continued)
(exercise), 7 years (control). No baseline characteristics given for drop-outs
Inclusion criteria: Clinical diagnosis of PD, 40-80 years of age, Hoehn and Yahr stages 1-3. Exclusion
criteria: medical conditions that limit physical activity, dementia or significant cognitive impairment
MMSE < 20, depression or other psychiatric disorder Beck Depression Inventory II score > 20, other
neurological conditions
Interventions Exercise and education: 1 hour and 15 min weekly of education delivered by physiotherapist, occupa-
tional therapist, speech language therapist, dietician, clinical psychologist and social worker. Education
consisted of active learning methods, action plan development and discussion to complete each session.
Report and discussion of action plan success/barriers to success at beginning of each session. An hour
and 15 min twice weekly session of exercise which consisted of warm up, cool down, flexibility and
strengthening exercises, posture and balance training, progressive aerobic training and functional task
training e.g. sit-to-stand etc
Exercise: As above, an hour 15 min twice weekly.
Control: No intervention.
It was not stated whether drug therapy was kept constant during the trial
Outcomes PDQ-8.
Stanford Self-Efficacy for managing chronic disease scale.
North Western University Disability Scale.
Schwab and England ADL Scale.
Activities Balance Confidence Scale.
Timed Up & Go.
Not stated when examinations took place.
Notes Abstract and presentation slides only.
The education and exercise and exercise only arms assessed were suitably similar and were therefore
combined to give one comparison of exercise
Average attendance of the education and exercise classes ranged from 79.4% to 85.5%
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Low risk
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe High risk 15% withdrawals
Cointerventions Constant Unclear risk It was not stated whether drug therapy was kept
constant during the trial
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Klassen 2007 (Continued)
Blinded Assessors Low risk Assessors were blinded to group allocation.
Kurtais 2008
Methods Parallel-group design.
Method of randomisation not stated.
Method of analysis not described.
Treated as outpatients 3 times a week for 6 weeks for a total period of 12 hours (40 minute sessions)
Assessed at baseline and 7 weeks after baseline assessments.
Assessors were blinded.
Participants 13 participants in the treadmill group and 14 in the control group. 1 drop-out in the treadmill group
and 2 in the control group
No baseline characteristics given for drop-outs. Participants’ mean age 63.8 years (treadmill), 65.7 years
(control); male/female 5/7 (treadmill), 7/5 (control); Hoehn and Yahr 2.5 (treadmill), 2.2 (placebo).
Duration of PD 5.3 years (treadmill), 5.4 years (control)
Inclusion criteria: Stable antiparkinsonian medication, ability to walk independently, not participated
in a rehabilitation program in the previous 3 months
Exclusion criteria: severe cognitive impairments or severemusculoskeletal, cardiopulmonary, neurologic
or other system disorders
Interventions Treadmill: gait training on a treadmill 3 times a week, attaining 70% to 80% of maximal heart rate.
Either speed or incline was gradually increased over time
Control: Untreated.
Drug therapy was stable during the trial.
Outcomes 20-m walking time.
Timed U-turn task.
Turning around a chair.
Climbing up and down a flight of stairs in participants preferred speed
Standing on one foot.
Standing up from an armless chair.
Rate global physical status.
Cardiopulmonary fitness levels.
Examinations were done during the participants ’on’ phase.
Notes Both groups were taught exercises to maintain flexibility and range of motion
One patient from the treadmill group was excluded due to non-compliance
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
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Kurtais 2008 (Continued)
Similarity at Baseline Low risk
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe High risk 11% withdrawals.
Cointerventions Constant Low risk Drug therapy was stable during the trial.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Lehman 2005
Methods Parallel-group design.
Method of randomisation not stated.
Method of analysis not described.
Treated as outpatients for 10 days over 2 weeks.
Assessed at baseline, immediately after, 1 week after and 1 month after intervention
Participants 5 participants in the cueing group and 6 participants in the control group. No drop-outs described
Participants’ mean age, 78 years (cueing), 74 years (control). Male/female ratio, 4/1 (cueing), 4/2
(control). Mean Hoehn and Yahr not stated. Duration of PD 7 years (cueing), 6.1 years (control)
Inclusion criteria: participants with gait impairment due to PD, early stage PD. Exclusion criteria:
persons with other neurological and/or orthopaedic impairments that could not walk the distances
required of the training program were excluded
Interventions Cueing: 10 day training programme of walking 1800 feet per day with instructions to ’take long steps’.
One trip down the 30 foot pathway is a length. Each training set consisted of 20 lengths. Participants
completed 3 training sets each day
Controls: No change in lifestyle or medication.
Drug therapy was not described.
Outcomes Step length.
Velocity.
Cadence.
Examinations took place at the same time each day.
Notes Data on graphs - limited data.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
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Lehman 2005 (Continued)
Similarity at Baseline Low risk
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe Unclear risk No drop-outs described.
Cointerventions Constant Unclear risk Drug therapy was not described.
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
Mak 2008
Methods Parallel-group design.
Participants randomly allocated to groups by drawing lots.
Method of analysis not described.
Treated as outpatients for 4 hours (audio-visual), 6 hours (exercise) over 4 weeks
Assessed at baseline, at 2 weeks, immediately after and 2 weeks after treatment had ended
Assessor was blinded.
Participants 21 participants in the cueing group, 21 participants in the exercise group and 18 in the control group.
2 drop-outs from the cueing group, 2 from the exercise group and 4 from the control group
No baseline characteristics given for drop-outs. Participants’ mean age 63 (cueing), 66 (exercise), 63
(control). No data given for the sex of participants. Hoehn and Yahr stage 2.8 (cueing), 2.7 (exercise)
and 2.7 (control). Duration of PD 5.9 years (cueing), 6.1 years (exercise), 5.9 years (control)
Inclusion criteria: diagnosed with PD according to Quinn, stable on anti-PD medications without
dyskinesia, orthopaedic, arthritic or heart problems, aged between 50-75 years old, perform sit to stand
independently, can follow instructions. No exclusion criteria stated
Interventions Cueing: Audio-visual cued task-specific training for 20 min three times per week. Received cued sit-to-
stand training using Equitest-Balance Master. Visual cue was given on a computer screen with verbal
command as auditory cue. Each task lasted 2 min, repeated once with a 30 second rests in between
Exercise: 45 min of conventional exercise twice a week. Conventional mobility and strengthening
exercises for flexors and extensors of trunk, hips, knees and ankles followed by sit-to-stand practice
Control: No treatment.
Drugs stable during therapy.
Outcomes Peak horizontal velocity (used in meta-analysis).
Peak vertical velocity.
Movement time.
3D Kinematics data of sit-to-stand.
Not stated when during the day tests took place.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Mak 2008 (Continued)
Eligibility Criteria Low risk
Randomisation Method High risk Drawing lots.
Concealment of Allocation High risk Drawing lots.
Similarity at Baseline Low risk
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe High risk 13% withdrawals.
Cointerventions Constant Low risk Drugs stable during therapy.
Blinded Assessors Low risk Assessor was blinded to group allocation.
Marjama-Lyons 2002
Methods Parallel-group design.
Method of randomisation not stated.
Method of analysis not described.
Treated as outpatients for 24 hours over 12 weeks.
Assessed at baseline and immediately after treatment.
Assessors were blinded.
Participants 30 participants. No drop-outs were described.
No baseline characteristics available.
Inclusion criteria: Levodopa responsive PD, Hoehn and Yahr Stage 1.5-3. No exclusion criteria
Interventions Martial arts: Two one hour weekly Tai Chi classes.
Control: Continued baseline exercise program and added no new exercises
Drug therapy was stable during the study.
Outcomes UPDRS motor score (part III).
Fall frequency form.
Balance master Limits of Stability.
Global Assessment of Change.
Examinations took place when participants were in the ’on’ state
Notes All participants did not practice Tai Chi before entry.
Abstract. No means and SDs, just P values available.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
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Marjama-Lyons 2002 (Continued)
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Unclear risk No baseline characteristics provided.
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe Unclear risk Drop-outs not described.
Cointerventions Constant Low risk Drug therapy was stable during study.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Meek 2010
Methods Parallel-group design.
Participants were randomised using computer-generated random block sizes of four
The data were analysed on an basis.
Treated as outpatients for 12 sessions over 12 weeks.
Assessed at baseline and immediately after treatment, and at 6 months
Assessor was blinded.
Participants 20 participants in the exercise group and 19 in the control group. 1 drop-out in the control group
Participants mean age, 63.4 years (exercise), 64.9 years (control); male/female ratio 15/5 (exercise), 16/
3 (control); mean duration of PD 5.1 years (exercise), 4.7 (control). Mean Hoehn and Yahr was not
reported
Inclusion criteria: A diagnosis of idiopathic PD, aged 18 years or over, no cognitive, sensory or psycho-
logical impairments that may prevent engagement in participation in the study or put the participant
at risk (judged by the referring clinician), able to participate in the study for its full duration, able to
walk 10m using any aid or assistance required. Exclusion criteria: Participants unable to meet inclu-
sion criteria, or those unwilling to participate, participants with additional impairments resulting in a
restriction of mobility, or any contraindications to exercise
Interventions Exercise: collaborated with fitness instructors to design a 3-month individualised, progressive exercise
program
Control: received usual care.
Drug therapy was allowed to change during the study.
Outcomes Physical Activity Scale for the Elderly.
Accelerometer monitored physical activity.
10-m walk test.
2-min walk test.
Lower limb muscle strength and grip strength.
Fatigue severity scale.
PDQ-39.
Falls.
There were no constraints on timing of assessments.
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Meek 2010 (Continued)
Notes Abstract and further information provide by author.
Gym attendance during the pooled intervention periods was high overall, with a mean of 14.5 visits
and median of 12 visits
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Low risk Computer-generated random block sizes of four.
Concealment of Allocation Low risk Randomisation done centrally.
Similarity at Baseline Low risk
Intention-to-Treat Analysis Low risk Intention-to-treat analysis.
Withdrawals Describe Low risk 1 drop-out in the control group (3%).
Cointerventions Constant Unclear risk Drug therapy was allowed to change during the
study.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Nieuwboer 2007
Methods Cross-over design.
Participants were randomly allocated in permuted blocks of six to an early or late intervention group
by an independent investigator not involved in data analysis. Allocation was concealed by the use of
opaque sealed envelopes
The data were analysed on an intention-to-treat basis.
Treated at home for 4.5 hours over 3 weeks.
Assessed at baseline, immediately after 1st and 2nd treatment and at 12 weeks
Assessors were blinded.
Participants 76 participants in the cueing group and 77 in the control group. 1 drop-out in the cueing group
Participants’ mean age, 66.9 years (cueing), 67.2 years (control). Male/female ratio 48/28 (cueing), 40/
37 (control). Hoehn and Yahr 2.7 (cueing), 2.8 (control). Mean duration of PD 7 years (cueing), 8
years (control)
Inclusion criteria: Diagnosis of Idiopathic PD (defined by the UK Brain Bank Criteria), Hoehn and
Yahr stage 2-4, showing mild to severe gait disturbance with score > 1 on the UPDRS item 29, stable
drug usage, age 18-80 years. Exclusion criteria: undergone DBS or stereotactic neurosurgery, had cogni-
tive impairment (MMSE < 24), had disorders interfering with participation in cueing training includ-
ing neurological (stroke, multiple sclerosis, tumour), cardiopulmonary (chronic obstructive disorders,
angina pectoris) and orthopaedic (osteoarthritis, rheumatoid arthritis and back pain) conditions, had
predictable and long lasting off periods (score 1 on item 37 and score > 2 on item 39 on UPDRS). Had
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Nieuwboer 2007 (Continued)
participated in a physio programme 2 months before starting the trial
Interventions Cueing: Cueing programme delivered at home over 3 weeks by 1 therapist in 9 sessions lasting 30
min. A prototype cueing device specifically developed for the study provided 3 rhythmical cueing
modalities: 1. auditory (a beep delivered through an ear piece), 2. visual (light flashes delivered through
a light-emitting diode attached to a pair of glasses), 3. somatosensory (pulsed vibrations delivered by a
miniature cylinder worn under a wristband). Participants tried all cueing modalities in the first week,
but trained with their preferred modality. Cued practice was applied during a variety of tasks and aimed
to improve step length and walking speed, prevent freezing episodes and improve balance
Control: No training.
Drug therapy was kept constant throughout the trial.
Outcomes Posture and gait score.
Gait and balance measures (including 10-m test of walking, gait speed, step length, step frequency,
functional reach, timed single leg and tandem stance, Freezing of Gait Questionnaire, Timed Up and
Go Test
Activity measures (including Nottingham Extended Activities of Daily Living Index, Falls Efficacy
Scale)
Participation measures (including Parkinson’s Disease Questionnaire-39, Carer Strain Index)
Falls diary.
Assessments were performed at the same time of day when participant was in the ’on’ phase approxi-
mately 1 hour after drug intake
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Low risk Permuted block size of 6.
Concealment of Allocation High risk Sealed envelopes.
Similarity at Baseline Low risk
Intention-to-Treat Analysis Low risk The data were analysed on an intention-to-treat
basis.
Withdrawals Describe Low risk 1 drop-out in the cueing group (<1%).
Cointerventions Constant Low risk All medication remained constant.
Blinded Assessors Low risk Assessors were blinded to group allocation.
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Protas 2005
Methods Parallel-group design.
Method of randomisation not stated.
Method of data analysis not described.
Treated as outpatients for 24 hours over 8 weeks.
Assessed at baseline and immediately after treatment.
Assessors were blinded.
Participants 9 participants in both groups. No drop-outs described.
Participants’ mean age 71.3 years (treadmill), 73.7 years (control); male/female all male participants for
both groups. Mean Hoehn and Yahr 2.8 (treadmill), 2.9 (control). Duration of PD 7.1 years (treadmill)
, 8.1 years (control)
Inclusion criteria: Idiopathic PD, postural instability-gait difficulty predominant PD, experiences with
freezing episodes, and or history of falls, stable regimen of antiparkinsonian medications, ability to
stand and walk with or without assistance, stage 2 or 3 Hoehn and Yahr, scores of moderate or higher
on all scales on the Neurobehavioural Cognitive Status Examination (Cognistat). No exclusion criteria
Interventions Treadmill: Gait and step training 3 times per week. Using a harness for safety the participant walks
forward on a treadmill at fastest speed for 5-7 min, backwards at fastest self-selected speed for 5-7 min.
Then left and right sideways walking at fastest selected speed for 2-3 min each way. Participants then
had 5 min rest before starting step training, which consisted of turning on the treadmill suddenly to
perturb the participant’s standing balance (15-20 forward and backward perturbations, 10-15 left and
right perturbations)
Control: No intervention.
Drug therapy was stable throughout the trial.
Outcomes Gait speed.
Cadence.
Stride length.
5-Step test.
Reports of falls.
Freezing of gait.
Assessments took place when participants were at their best ’on’ state
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Low risk
Intention-to-Treat Analysis Unclear risk Method of data analysis not described.
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Protas 2005 (Continued)
Withdrawals Describe Unclear risk No drop-outs described.
Cointerventions Constant Low risk Drug therapy was stable throughout the trial.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Purchas 2007
Methods Cross-over design.
Method of randomisation not stated.
Method of data analysis not described.
1 session per week for a total of 12 weeks.
Assessed at baseline and immediately after 1st and 2nd treatment
Not stated whether the assessors were blinded.
Participants 10 participants in the martial arts group and 10 participants in the control group. One drop-out from
both groups
Mean age of participants 70 years in both groups. Male/female ratio, 7/2 (martial arts), 4/5 (control).
Mean Hoehn and Yahr 2 (martial arts), 2.3 (control). No baseline characteristics given for drop-outs
Inclusion criteria: maintenance phase of PD. No exclusion criteria
Interventions Martial arts: 1 hour weekly Tai Chi training.
Control: no treatment.
Drug therapy not described.
Outcomes Timed Up and Go Test.
PDQ-39.
UPDRS.
Hoehn and Yahr stage.
Falls diary.
Not stated when during the day examinations took place.
Notes Abstract and poster only.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Unclear risk Maintenance phase of PD.
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Low risk
Intention-to-Treat Analysis Unclear risk Method of data analysis not described.
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Purchas 2007 (Continued)
Withdrawals Describe Low risk 10% drop-out
Cointerventions Constant Unclear risk Drug therapy was not described.
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
Sage 2009a
Methods Parallel-group design.
Method of randomisation not stated.
Data analysed on an intention-to-treat basis.
Treated as outpatients for 18 hours (exercise), 20-24 hours (PDSAFEx) over 10-12 weeks
Assessed at baseline and after treatment.
Assessors were blinded.
Participants 17 participants in the exercise group, 21 participants in the PDSAFEx group and 15 in control. 4 drop-
outs (exercise) and 3 drop-outs (PDSAFEx)
Participants’ mean age 65.1 years (exercise), 64.2 years (PDSAFEx), 68.6 years (control). Male/female
ratio, 6/7 (exercise), 12/6 (PDSAFEx), 7/8 (control). Hoehn and Yahr score not given. Duration of PD
3.2 years (exercise), 4.7 years (PDSAFEx) and 2.5 years (control). No baseline characteristics given for
drop-outs
Inclusion criteria: diagnosis of idiopathic PDwith no othermajor medical, physiological or neurological
problem, a stable medication schedule, mild to moderate PD defined as a score of less than 35 on
UPDRS motor section
Interventions Exercise: lower limb aerobic training, exercise for 30 min (5 min warm up, 20 min aerobic training, 5
min cool down) three times a week in groups of 4 on Biostep semi-recumbent elliptical’s in the seated
position. The machine was primarily leg driven with arms moving in a coordinated pattern. Intensity
maintained by achieving a pace of 50 RPM, a heart rate of 60% to 75% of age related max and a Borg
rate of perceived exertion of below 5
PDSAFEx: Sensory attention focused exercise for 40-60 min three times a week. 20-30 min of non-
aerobic gait exercises focused on body coordination followed by 20-30 min of sensory attention exercises
utilising latex Thera-bands® attached to arm rests of office chairs. Exercises were completed with eyes
closed and cued to the sensory feedback from specific portions of each exercise. Examples of exercises,
tandem walking for balance and coordination, side stretches down side of chair for sensory feedback
Control: Non-exercise control group, maintained regular activity level
Drug therapy remained unchanged during the trial.
Outcomes UPDRS III.
Timed Up and Go.
Spatiotemporal aspects of gait.
Assessments tookplacewhenparticipantswere a ’peak’ dose (approximately 90min after administration)
Notes 3-arm trial.
The PD SAFEx and exercise arms assessed were suitably similar and were therefore combined to give
one comparison of exercise
Both exercise groups attended an equivalent number of training sessions, overall 90%
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Sage 2009a (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Low risk
Intention-to-Treat Analysis Low risk Statisicial analysis was done using intention-to-
treat principles
Withdrawals Describe High risk 13% withdrawals.
Cointerventions Constant Low risk Drug therapy remained unchanged during the
trial.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Schenkman 1998
Methods Parallel-group design.
Participants were stratified according to gender and then randomised using computer-generated assign-
ment
Randomisation schedule kept in office of statistician until participants were assigned
Method of data analysis not described.
Treated as outpatients for 30 hours over 10-13 weeks.
Assessed at baseline and immediately after treatment.
Assessors were blinded.
Participants 27 participants in exercise group, 24 participants in control group. 4 drop-outs from exercise group, 1
from control group
No baseline characteristics given for drop-outs. Participants mean age 70.6 years (exercise), 71.2 years
(control); male/female 18/5 (exercise), 16/7 (control); Hoehn and Yahr 2.6 (exercise), 2.7 (control)
Inclusion criteria: PD as diagnosed by a neurologist, Hoehn and Yahr stage 2 or 3, functional axial
rotation of 120 degrees or less to either side.
Exclusion criteria: Hospitalised within last 3 months, PD drugs changed in last month, other neuro-
logical disorders, Folstein MMSE < 23
Interventions Exercise: Individual exercises to improve spinal flexibility and coordinated movement. Standardised
programme included a series of exercises divided into 7 graduated stages, from supine to standing.
Exercises learned at each stage are continued throughout with progressively higher level activities added.
Exercises are incorporated into daily routine at end of formal training sessions
Control: No treatment. (’Wait listed’ for exercise programme)
Drug therapy constant during trial.
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Schenkman 1998 (Continued)
Outcomes Functional axial rotation.
Functional reach.
Timed tests.
Timed walk.
Cervical and lumbar range of motion.
Walking velocity.
Participants with fluctuations assessed during ’on’ time.
Notes Abstract, further information obtained from author.
All 46 participants completed 30 treatment sessions within their allotted time
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Low risk Computer-generated assignment.
Concealment of Allocation Low risk Randomisation schedule kept in office of statisti-
cian until participants were assigned
Similarity at Baseline Low risk
Intention-to-Treat Analysis Unclear risk Method of data analysis not described.
Withdrawals Describe Low risk 10% withdrawals.
Cointerventions Constant Low risk Drug therapy was kept constant during the trial.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Schilling 2008
Methods Parallel-group design.
Participants were gender matched then randomly assigned. Method of randomisation not stated
Method of data analysis not described.
Treated as outpatients for 16 sessions of an unspecified time over 8 weeks
Assessed at baseline and immediately after treatment.
Participants 9 participants in the exercise group and 9 participants in the control group. 1 drop-out form the exercise
group, 2 drop-outs from the control group
Participants’ mean age 61.3 years (exercise), 57 years (control); male/female 5/4 (exercise), 6/3 (control)
; Hoehn and Yahr 2.1 (exercise), 1.9 (control)
Inclusion criteria: mild to moderate PD, Hoehn and Yahr stage 1-2.5, ability to walk a 20-foot path,
turn and return to the start without use of assistive device. Exclusion criteria: orthostatic hypotension,
dementia (MMSE < 24), other significant co-morbidities (i.e. stroke, severe degenerative osteoarthritis)
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Schilling 2008 (Continued)
, other causes of Parkinsonism such as PSP, vascular PD and multiple system atrophy as determined by
board-certified neurologist
Interventions Exercise: moderate volume, high-load lower-body resistance training twice weekly. After a warm-up
participants performed three sets of 5-8 repetitions for the leg press, seated leg curl, and calf press under
direct supervision of a Certified Strength and Conditioning Specialist. Participants were instructed to
lift the weight as fast a possible with good form and to slowly return the weight to the start position.
Progression was planned so that when eight repetitions could be completed for all the sets the weight
was increased by 5% to 10%
Control: Continue standard care.
Drug therapy was not described.
Outcomes Maximum strength for the lower body.
Activities-Specific Balance Confidence.
Timed Up and Go.
6-minute Walk Test.
All testing done when participants were in their optimally medicated state, typically within 30 min to
2 hours of their first morning dose
Notes Control group were given the opportunity to complete the training intervention after the 8week control
period
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Method of randomisation not stated.
Concealment of Allocation Unclear risk Method of randomisation not stated.
Similarity at Baseline Low risk
Intention-to-Treat Analysis Unclear risk Method of data analysis not described.
Withdrawals Describe High risk 17% withdrawals.
Cointerventions Constant Unclear risk Drug therapy was not described.
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
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Schmitz-Hubsch 2006
Methods Parallel-group design.
Participants were sorted randomly, matched for disease severity, presence or absence of dyskinesia and
type of clinical manifestation. Randomisation was carried out using a list of pseudonyms generated by
one investigator and transferred by fax to a 2nd investigator
The data were analysed on an intention-to-treat basis.
Treated as outpatients for 8 hours over 8 weeks, then for 0 hours for 8 weeks then 8 hours for 8 weeks.
Total of 16 hours over 24 weeks
Assessed at baseline, 3, 6 and 12 months.
Not stated whether assessors were blinded.
Participants 32 participants in the martial arts group and 24 in the control group. 2 drop-outs in the martial arts
group and 5 in the control group
Participants’ mean age, 64 years (martial arts), 63 years (control); male/female 24/8 (martial arts), 19/5
(control). Hoehn and Yahr score not given. Duration of PD 6 years (martial arts) and 5.6 years (control)
Inclusion criteria: participants diagnosed with PD according to the UK Brain Bank Criteria at any stage
of the disease with or without motor complications, MMSE > 24. Exclusion criteria: previous practical
experience with Qigong, recent (< 1 month) or planned change of medication, signs of central nervous
system disease other than PD e.g. aphasia or dementia (defined by MMSE < 24)
Interventions Martial Arts: 1 hour weekly group lesson of Qigong delivered by an experienced teacher. Exercises
were carried out standing or in the sitting position adjusted to participants physical abilities. Teacher
repeatedly stressed importance of home self-exercise
Control: no intervention.
Drug therapy varied throughout the trial.
Outcomes UPDRS III.
PDQ-39.
Montogmery-Asperg Depression Rating Scale.
Non-motor symptoms.
Self-reporting questionnaire.
Assessments were carried out when participants were in the ’on’ state (time of optimal medication effect
as defined by the participant). Follow-up assessments were done at similar times of the day
Notes Participants were asked not to change their medication during the study but if their medical condition
required adaptations this would not lead to exclusion
Compliance at one year follow-up was fair.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method High risk List of pseudonyms.
Concealment of Allocation High risk Randomisation was carried out using a list of
pseudonyms generated by one investigator and
transferred by fax to a 2nd investigator
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Schmitz-Hubsch 2006 (Continued)
Similarity at Baseline Low risk
Intention-to-Treat Analysis Low risk All analyses were carried out on an intention-to-
treat-basis
Withdrawals Describe High risk 13% withdrawals.
Cointerventions Constant Unclear risk Drug therapy varied throughout the trial.
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
Shankar 2008
Methods Parallel-group design.
Random allocation using computer-generated random list.
Method of analysis not described.
Treated as an outpatient for 36 hours over 3 months.
Assessed at baseline and immediately after treatment.
Assessors were blinded.
Participants 14 participants in the cueing group and 14 in the control group. No drop-outs described
Participants’ mean age, 70 years (cueing), 62 years (control); male/female 6/8 (cueing), 8/6 (control),
mean Hoehn and Yahr score 2.4 (cueing), 2.3 (control). Duration of PD 7.5 years (cueing), 7.9 years
(control)
Inclusion criteria: diagnosis of idiopathic PD as per UK Brain Bank criteria, Hoehn Yahr disease stages
2 and 3, stable PD medication for 1 month prior to baseline visit, ability to walk with headphones
unaided for 30 minutes three times per week, absence of pre-existing walking to music. Exclusion
criteria: presence of dementia (MMSE < 26), presence of co-morbidities that affect the ability to walk,
hearing deficits
Interventions Cueing: walking for 30 min three times per week whilst listening to a battery of musical pieces. Music
was self-selected based upon participant input and cadence-matched to the participant’s ideal walking
speed
Control: maintained their normal walking activity.
Minor medication changes allowed, as deemed appropriate by team neurologist
Outcomes Gait and Balance Scale.
UPDRS III.
Adjusted PDQ-39.
Activities-Specific Balance Confidence Scale.
Not stated when examinations took place.
Notes Abstract. Information on trial quality and data obtained from author
Risk of bias
Bias Authors’ judgement Support for judgement
62Physiotherapy versus placebo or no intervention in Parkinson’s disease (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Shankar 2008 (Continued)
Eligibility Criteria Low risk
Randomisation Method Low risk Computer-generated random list.
Similarity at Baseline Low risk
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe Unclear risk No drop-outs described.
Cointerventions Constant Unclear risk Minor medication changes allowed, as deemed ap-
propriate by team neurologist
Blinded Assessors Low risk Assessors were blinded to group allocation.
Shankar 2009
Methods Parallel-group design.
Randomisation method not stated.
Method of analysis not described.
Treated as outpatients for 8 hours over 8 weeks.
Assessed at baseline and immediately after treatment.
Assessor was blinded.
Participants 10 participants in the treadmill + cueing group, 10 participants in the cueing group. No drop-outs
described
Baseline characteristics only given for all three treatment groups combined - Mean age 64.4 years, 62%
were male
Inclusion criteria: Moderate PD. No exclusion criteria.
Interventions Treadmill + cueing: Walking on the treadmill with music for 30 min twice a week. Music was selected
based upon participant input and cadence-matched to the participant’s preferred walking speed
Treadmill: Walking on the treadmill without music for 30 min twice a week
Cueing: Listening to music for 30 min twice a week.
Drug therapy was not described.
Outcomes Gait and Balance Scale.
UPDRS III.
PDQ-39.
Not stated when examinations took place.
Notes Abstract only.
The 3rd arm, treadmill only was excluded from our analysis
Risk of bias
Bias Authors’ judgement Support for judgement
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Shankar 2009 (Continued)
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Unclear risk Baseline characteristics only given for all three
treatments groups combined
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe Unclear risk No drop-outs described.
Cointerventions Constant Unclear risk Drug therapy was not described.
Credible Placebo Low risk
Blinded Assessors Low risk Assessor was blinded to group allocation.
Stozek 2003
Methods Parallel-group design.
Method of randomisation not stated.
Method of analysis not described.
Treated as outpatients for 56 hours over 4 weeks.
Assessed at baseline, immediately and 1 month after treatment
Not stated whether assessors were blinded or not.
Participants 30 participants in the exercise group and 31 participants in the control group. No drop-outs described
Participants’ mean age 64 years (exercise), 67 years (control); Male/female 13/17 (exercise), 16/15
(control); Hoehn and Yahr 2.3 for both groups. Mean duration of PD 4.6 years (exercise), 4.3 years
(control)
Inclusion criteria: Idiopathic PD diagnosed by a neurologist, disease stage based on theHoehn and Yahr
scale 1.5-beginning of 3, stable pharmacological treatment for at least the last 3 months, age 35-85, no
other neurological disease or serious movement disorders, no contraindications for physical exercise,
participants written consent to participate in the study
Interventions Exercise: Complex rehabilitation for 2 hours twice daily for first 2 weeks then once a day three times
a week for 2 weeks for a total of 28 sessions. Sensory reinforcements were used during all exercises:
verbal, visual, auditory, extero- and proprioceptive stimulation. Complex rehabilitation consisted of:
relaxation and breathing exercises, exercises increasing the range of movement, functional exercises,
exercises for posture, balance, gait, music-dance exercises, mimic exercises of facial muscle and tongue,
articulation and voice exercises, group therapy and patient education
Control: Without rehabilitation.
It was not stated whether drug therapy was stable throughout the trial
Outcomes Functional reach test.
Tinetti’s Balance Performance Oriented Mobility Assessment.
Static and dynamic balance.
Timed Up and Go.
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Stozek 2003 (Continued)
10m walk.
Locomotion test.
360° turn.
All assessments were carried out during one day in the morning when participants were in the ’on’
phase
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Low risk
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe Unclear risk No drop-outs described.
Cointerventions Constant Unclear risk It was not stated whether drug therapy was stable
throughout trial
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
Thaut 1996
Methods Parallel-group design.
Randomised by a ’random draw’, but concealment of allocation unclear
Method of analysis not described.
Treated at home or in the community for 10.5 hours over 3 weeks
Assessed in the laboratory at baseline, and immediately after treatment
Not stated whether the assessors were blinded.
Participants 15 participants in the cueing group, 11 participants in the exercise and 11 participants in control group.
No drop-outs described
Participants’ mean age, 69 (cueing), 74 (exercise), 71 (control);Male/female 10/5 (cueing) 8/3 (exercise)
, 8/3 (control); Hoehn and Yahr 2.4 (cueing), 2.5 (exercise), 2.6 (control). Mean duration of PD 7.2
years (cueing), 5.4 years (exercise), 8.5 years (control)
Inclusion criteria: Idiopathic PD with significant gait deficits regarding velocity, stride length and
cadence but able to walk without physical assistance. No exclusion criteria
Interventions Cueing: Exercised for 30 min daily according to a prescribed program using rhythmic auditory stim-
ulation (RAS). The RAS program consisted of walking on a flat surface, stair stepping, and stop-and-
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Thaut 1996 (Continued)
go exercises to rhythmically accentuated music at three different tempos. The tempos were labelled
’normal’, ’quick’ and ’fast’
Exercise (self-paced therapy, SPT): Performed their 30 min daily walking sessions without RAS, follow-
ing the same training protocol and training exercises for the same length of time. Walking was divided
equally into walking at normal pace, quick pace and fast pace
Control: No treatment.
Drugs stable during therapy.
Outcomes Walk velocity.
Stride cadence.
Stride length.
EMG analysis on leg muscles.
Footfall pattern.
All testing done 90-120 minutes after first medication intake in morning
Notes 3 arms to trial; RAS, SPT and no treatment. SPT vs. RAS are examined in ’A comparison of physio-
therapy techniques for participants with Parkinson’s disease.’ Cochrane review
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method High risk Random draw.
Concealment of Allocation Unclear risk No information provided to allow assessment.
Similarity at Baseline Low risk
Intention-to-Treat Analysis Unclear risk Method of analysis not described.
Withdrawals Describe Unclear risk No drop-outs described.
Cointerventions Constant Low risk Medication remained stable throughout study.
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
MMSE: Mini-Mental State Examination
PD: Parkinson’s disease
QoL: quality of life
SD: standard deviation
UPDRS: Unified Parkinson’s Disease Rating Scale
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bergen 2002 No outcome measures relevant to our review.
Blackington 2002 Initially identified as a suitable study for inclusion but was excluded due to the number of drop-outs (47%;
final number of participants analysed n=8), which left the two groups unmatched by age and duration of
Parkinson’s disease
Bridgewater 1997 Although this trial was designed as an RCT, after discussion with the authors it was discovered that themethod
of randomisationwas compromised. ’In order of response to advertising, participants were allocated alternately
to group A (period of exercise then no exercise) and group B (control, then complimentary exercise classes)
.’ Although alternate allocation is an acceptable method of randomisation, the authors went on to change
participants from group A to B if their personal circumstances dictated that they would be unavailable for the
physiotherapy e.g. if they were leaving the state on holiday. We feel that this compromised the randomisation
procedure and therefore excluded the trial
Byl 2009 After email correspondence with the author, this trial was found out not to be randomised
Christofoletti 2010 Excluded as although the abstract for the study states ’randomised controlled trial’, after translating the
full paper the study did not appear to be randomised; ’allocated to groups on convenience basis, following
availability of participants at treatment site’. Attempted to contact author to clarify randomisation method
but were unsuccessful
Cianci 2010 Excluded as confounded due to use of rolling walker.
Comella 1994 The study did not report outcomes for the first assessment period and therefore has been excluded to prevent
any bias of carry over or order effects
Forkink 1996 No outcome measures relevant to our review.
Formisano 1992 Although this trial was controlled, the authors did not state that the allocation of the participants into the
two groups was random
Gibberd 1981 The study did not report outcomes for the first assessment period and therefore has been excluded to prevent
any bias of carry-over or order effects
Guo 2009 Multidisciplinary rehabilitation trail. Percentage component of physiotherapy was not specified, therefore
unable to differentiate the contribution of physiotherapy to any change in the outcome measures
Haas 2006 Excluded as the study was a randomised cross-over over a couple of hours
Hurwitz 1989 No outcome measures relevant to our review.
Katsikitis 1996 No outcome measures relevant to our review.
King 2009 Excluded as the study was a randomised cross-over on the same day
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(Continued)
Patti 1996 Multidisciplinary rehabilitation trail. Percentage component of physiotherapy was not specified, therefore
unable to differentiate the contribution of physiotherapy to any change in the outcome measures
Pohl 2003 Randomised multiple intervention cross-over, over 4 consecutive days. Randomisation was of the sequence
of the interventions, therefore not RCT
Sage 2009b After contacting the author it was found that the study was not properly randomised
Stallibrass 2002 The method of therapy used - Alexander Technique - is not used by physiotherapists. Therefore this trial was
excluded
Tickle-Degnen 2010 Multidisciplinary rehabilitation trail. Percentage component of physiotherapy was not specified, therefore
unable to differentiate the contribution of physiotherapy to any change in the outcome measures
Van Gerpen 2010 Excluded as confounded due to use of four-wheeled walker.
Wade 2003 Multidisciplinary rehabilitation trail. Percentage component of physiotherapy was not specified, therefore
unable to differentiate the contribution of physiotherapy to any change in the outcome measures
Wells 1999 Although not stated in the text, after personal communication with the author this trial was determined
to be an RCT. However the method of therapy used - osteopathic manipulative treatment - is not used by
physiotherapists. Therefore this trial was excluded
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
Canning 2009
Trial name or title Exercise therapy for prevention of falls in people with Parkinson’s disease: a randomised controlled trial
Methods Parallel-group design.
Randomisation was stratified by falls history (0-10 falls in the previous 12 months/more than 10 falls in the
previous 12 months) using a computer-generated random number schedule with variable block sizes of 2-6.
Randomisation was performed centrally by an investigator not involved in recruitment or assessments
Assessors were blinded.
Participants 230 participants.
Inclusion criteria: Diagnosis of Idiopathic Parkinson’s disease. Adapted to their current antiparkinsonian
medication for at least 2 weeks. Aged 40 years or over. Able to walk independently (with or without walking
aid). Have a history of falls (at least one fall in the previous 12 months) or are at risk of falls
Exclusions criteria: Have a Mini-Mental State Examination score of < 24. Suffer from unstable cardiovascular
disease or other uncontrolled chronic conditions that would interfere with the safety and conduct of the
training and testing protocol or interpretation of the results
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Canning 2009 (Continued)
Interventions Exercise: 40-60 minute program of home-based balance and leg strength exercises three times a week for 6
months. Participants can choose to participate in a once a month exercise class (for 6 months) conducted by a
physiotherapist in association with their local Parkinson’s NSW/ACTSupport Group or hospital. Participants
will be provided with a booklet containing safety precautions, instructions and photographs of exercises for
use in exercise sessions at home, as well as information sheets detailing strategies for managing freezing. In
addition, they will be provided with a logbook for recording exercises completed and any adverse effects of
exercise. Participants will also receive standardised falls prevention advice and will be provided with a falls
diary for recording falls
Control: Will have standardised falls prevention advice and will be provided with a falls diary for recording
falls
Outcomes Falls diary*.
Parkinson’s Disease Falls Risk Score.
Maximal muscle strength, Knee extension (quadriceps).
Step test component from the Berg Balance Scale.
Short Physical Performance Battery.
Freezing of Gait Questionnaire.
SF12v2T M health survey.
Falls Efficacy Scale International questionnaire.
Habitual Physical Activity Questionnaire.
PDQ-39.
Positive and Negative Affect Schedule (PANAS).
Total cost*.
Tested at baseline and at the end of the 6 month intervention period. *Data collected monthly
Starting date 01/05/2008
Contact information Dr Colleen Canning (c.canning@usyd.edu.au).
Discipline of Physiotherapy, Faculty of Health Sciences, The University of Sydney
Notes Australian New Zealand Clinical Trials Registry Number: ACTRN12608000303347
Ledger 2008
Trial name or title A randomised controlled trial (RCT) to evaluate use of an auditory cueing device’s (IACD’s) on freezing and
gait in people with Parkinson’s disease (PD)
Methods Randomised using sealed, computer-generated random numbers.
Participants 47 participants.
Inclusion criteria: Parkinson’s disease, medically stable, willing to give informed consent, freeze at least once
per week (minimum score of 2 on item 3 of the FOGQ) for at least 2 seconds (minimum score of 1 on item
4 of FOGQ), MMSE score greater than 24
Exclusion criteria: attending physiotherapy at time of recruitment, unwilling to give informed consent, not
medically stable, cognitive impairment (MMSE score less than 24), acute co-morbidity that prevents mobility
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Ledger 2008 (Continued)
Interventions Cross-over trial.
Cueing: iPod containing and auditory cue in the form of a continuous metronome beat, individualised to the
participants walking frequency (less 10%). Participants instructed to listen to cueing when performing any
mobility-related tasks for 8 days
Control: iPod shuffle with no music or metronome beat for 8 days
Outcomes Freezing of Gait Questionnaire.
Timed Up and Go Test.
Modified Falls Efficacy Scale.
10-Metre Walk Test.
Tested on day 8, 15, 23 and at 3 months.
Starting date Study not yet open for recruitment.
Contact information Dr Emma K Stokes (estokes@tcd.ie).
Notes On days 1-8 of the trial both groups given an iPod with some music on to allow all participants to become
familiar with the device. They will be instructed to use the device only when sitting at home and that the
device should not be turned on when walking or performing any mobility related or daily tasks
NCT00727467.
Martin 2009
Trial name or title Home based rehabilitation to reduce falls in people with Parkinson’s disease (PD): a randomised controlled
trial
Methods Parallel-group design.
Participants 180 participants.
Inclusion criteria: Idiopathic Parkinson’s disease, living in the community, Hoehn and Yahr stage 1-4
Exclusion criteria: suffer from cardiopulmonary, musculoskeletal, endocrine or other medical condition that
prevents safe participation in a home exercise program, participant or their carer/family are unwilling to have
therapy and assessments in their home, unable to communicate in English, have dementia score MMSE score
< 24, unable to provide informed consent
Interventions Active intervention: 6-week individualised home-based rehabilitation program comprising a once-weekly 1
hour program delivered by a trained therapist, together with a once-weekly 1 hour self-directed exercise
program. The intervention is designed to provide participants with an integrated ’package’ of evidence based
therapy, including movement strategy training, strengthening and falls education
Active control: 6-week individualised home-based ’life skills’ program comprising a once-weekly 1 hour
program delivered by trained therapist, together with a once-weekly self-directed life skills home program.
The active control is designed to provide education on medication, managing stress, driving and other daily
activities and include content related to falls, physical exercise and gait rehabilitation
Outcomes Fall frequency and injuries*.
UPDRS total and motor.
PDQ-39.
EuroQOL*.
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Martin 2009 (Continued)
Tested at baseline, 6 weeks and at 12 months. * 12 months only
Starting date 01/08/2008
Contact information Dr C Martin (cmartin@unimelb.edu.au)
Centre for Health Exercise and Sports Medicine, School of Physiotherapy, The University of Melbourne
Notes ACTRN12608000390381
Schenkman 2009
Trial name or title Exercise, physical function and Parkinson’s disease
Methods 3-arm parallel-group design.
Participants
Interventions Exercise 1: General Endurance Training.
Exercise 2: PD Specific Flexibility and functional training.
Control: Usual care based on a booklet based on the American Parkinson Foundation
Outcomes Continuous-Scale Physical Functional Performance Test.
Functional Reach.
O2 Consumption at a set walking speed.
Assessed at baseline, after treatment and at 10 and 16 months
Starting date 11/04/2003
Contact information Nancy Shinowara (shinowara@nih.gov).
Notes Information obtained from CRISP/RePORT database.
Watts 2008
Trial name or title A randomized controlled trial of strategy training compared to exercises to prevent falls and improve mobility
in people with Parkinson’s disease
Methods 3-arm parallel-group design.
Randomised by telephone randomisation service.
Participants 330 participants.
Inclusion criteria: Neurologist-confirmed diagnosis of idiopathic Parkinson’s disease. Cognitively intact (a
MMSE score of > 24). Minimum age 18 years
Exclusion criteria: Other neurological disorders known to affect balance and gait. Cognitive impairment
(MMSE < 24). Currently taking tranquillizer medication. Inability to walk
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Watts 2008 (Continued)
Interventions Movement Strategy Training (MST): once-weekly 2 hour individualised program given for 8 weeks. Program
comprises of strategies to prevent falls, enhance balance and improvemobility, along with education about risk
factors for falls and general education about Parkinson’s disease. Participants will also receive a once-weekly
individualised and structured home program to reinforce the content of each outpatient session. The person
will also receive one home visit by an Occupational Therapist who will conduct a detailed environmental
analysis using a standardized home assessment checklist and recommend home modifications to minimize
falls risk
Progressive Strength Training (PST): Once-weekly 2 hour individualised program given for 8 weeks. Program
for functional strengthening of muscles such as quadriceps, hamstrings, calf, tibialis anterior, glutei, abductor
and trunk muscles plus education about methods to prevent falls and general education about Parkinson’s
disease. Each person will receive a strength program that is tailored to their individual needs and reinforced
by a once-weekly individualised and structured home program. An Occupational Therapist will perform one
home visit as above
Control: Once-weekly 2 hour outpatient social activity program (games, crafts, cooking, general education
about Parkinson’s) delivered by an Occupational Therapist over 8 weeks. Participants will also receive a once-
weekly individualised and structured home program of activities. During the program the person will receive
one home visit by a nurse to check on general well-being, mobility or physical function
Outcomes Falls frequency*.
Walking speed over 10 metres.
Locomotor function (Timed up and go test).
Activity limitation.
Measured at 3 and 12 months, *12months only.
Starting date 25/09/2006
Contact information Professor M Morris (m.morris@unimelb.edu.au).
School of Physiotherapy University of Melbourne.
Notes ACTRN12606000344594
Woo 2010
Trial name or title The effectiveness of physiotherapy interventions for patients with Parkinson’s disease
Methods 2 arm Parallel-group design
Participants Estimated enrolment: 112
Inclusion criteria: Stable medication usage. Hoehn and Yahr stage II to IV. At least 1 score of 2 or more for at
least 1 limb of either the tremor, rigidity, or bradykinesia item of the Unified Parkinson’s Disease Rating Scale
(UPDRS). Able to walk independently. No severe cognitive impairments (Mini-Mental State Examination -
Chinese Cantonese version) score greater than 24
Exclusion criteria: Other severe neurological, cardiopulmonary, or orthopedic disorders. Having participated
in a physiotherapy or rehabilitation program in previous 2 months
Interventions Physiotherapy intervention: Physiotherapy interventions including strengthening exercise, balance training,
gait training with visual cue, gait training with treadmill
Education intervention: Education classes.
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Woo 2010 (Continued)
Outcomes Movement Disorder Society-Unified Parkinson’s Disease Rating Scale
Levodopa equivalent daily dosage (LEDD)
Timed Up and Go Test
Activities-Specific Balance Confidence Scale (Chinese Version)
Parkinson’s Disease Questionnaire (Standard Chinese Version)
Number of injurious falls.
Starting date 03/2010
Contact information CWWoo (woocx@ha.org.hk).
Notes NCT01076712
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D A T A A N D A N A L Y S E S
Comparison 1. Gait Outcomes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 2- or 6- Minute Walk Test (m) 4 172 Mean Difference (IV, Fixed, 95% CI) 16.40 [1.90, 30.90]
1.1 Exercise v Control 3 98 Mean Difference (IV, Fixed, 95% CI) 10.14 [-5.70, 25.97]
1.2 Dance v Control 1 48 Mean Difference (IV, Fixed, 95% CI) 61.7 [-4.95, 128.35]
1.3 Martial Arts v Control 1 26 Mean Difference (IV, Fixed, 95% CI) 43.6 [0.71, 86.49]
2 10- or 20- m Walk Test (s) 4 169 Mean Difference (IV, Fixed, 95% CI) 0.40 [0.00, 0.80]
2.1 Exercise v Control 3 145 Mean Difference (IV, Fixed, 95% CI) 0.41 [0.02, 0.81]
2.2 Treadmill v Control 1 24 Mean Difference (IV, Fixed, 95% CI) -0.8 [-4.41, 2.81]
3 Velocity (m/s) 11 629 Mean Difference (IV, Fixed, 95% CI) 0.05 [0.02, 0.07]
3.1 General Physiotherapy v
Control
3 137 Mean Difference (IV, Fixed, 95% CI) 0.09 [0.01, 0.17]
3.2 Exercise v Control 4 146 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.01, 0.07]
3.3 Treadmill v Control 2 38 Mean Difference (IV, Fixed, 95% CI) 0.07 [-0.07, 0.21]
3.4 Cueing v Control 4 234 Mean Difference (IV, Fixed, 95% CI) 0.06 [0.02, 0.09]
3.5 Dance v Control 1 48 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.16, 0.22]
3.6 Martial Arts v Control 1 26 Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.22, 0.04]
4 Cadence (steps/min) 6 327 Mean Difference (IV, Fixed, 95% CI) -1.72 [-4.01, 0.58]
4.1 General Physiotherapy v
Control
1 20 Mean Difference (IV, Fixed, 95% CI) -2.40 [-11.12, 6.32]
4.2 Exercise v Control 2 68 Mean Difference (IV, Fixed, 95% CI) -1.70 [-6.30, 2.90]
4.3 Treadmill v Control 2 38 Mean Difference (IV, Fixed, 95% CI) -0.04 [-6.48, 6.39]
4.4 Cueing v Control 3 201 Mean Difference (IV, Fixed, 95% CI) -2.03 [-5.11, 1.05]
5 Stride Length (m) 5 202 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.02, 0.09]
5.1 General Physiotherapy v
Control
1 20 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.19, 0.15]
5.2 Exercise v Control 1 22 Mean Difference (IV, Fixed, 95% CI) 0.17 [-0.03, 0.37]
5.3 Treadmill v Control 2 38 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.07, 0.14]
5.4 Cueing v Control 2 48 Mean Difference (IV, Fixed, 95% CI) 0.09 [-0.02, 0.20]
5.5 Dance v Control 1 48 Mean Difference (IV, Fixed, 95% CI) 0.07 [-0.10, 0.24]
5.6 Martial Arts v Control 1 26 Mean Difference (IV, Fixed, 95% CI) -0.1 [-0.23, 0.03]
6 Step Length (m) 3 239 Mean Difference (IV, Fixed, 95% CI) 0.03 [8.27, 0.06]
6.1 General Physiotherapy v
Control
1 20 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.10, 0.06]
6.2 Exercise v Control 1 46 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.04, 0.09]
6.3 Treadmill v Control 1 20 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.08, 0.10]
6.4 Cueing v Control 1 153 Mean Difference (IV, Fixed, 95% CI) 0.04 [0.01, 0.07]
7 Freezing of Gait Questionnaire 3 246 Mean Difference (IV, Fixed, 95% CI) -1.19 [-2.54, 0.16]
7.1 Exercise v Control 1 45 Mean Difference (IV, Fixed, 95% CI) -2.40 [-5.76, 0.96]
7.2 Cueing v Control 1 153 Mean Difference (IV, Fixed, 95% CI) -0.87 [-2.43, 0.69]
7.3 Dance v Control 1 48 Mean Difference (IV, Fixed, 95% CI) -1.7 [-6.30, 2.90]
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Comparison 2. Functional Mobility and Balance Outcomes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Timed Up & Go (s) 7 495 Mean Difference (IV, Fixed, 95% CI) -0.61 [-1.06, -0.17]
1.1 Exercise v Control 5 268 Mean Difference (IV, Fixed, 95% CI) -0.22 [-0.93, 0.50]
1.2 Dance v Control 1 48 Mean Difference (IV, Fixed, 95% CI) -3.10 [-7.76, 1.56]
1.3 Cueing v Control 1 153 Mean Difference (IV, Fixed, 95% CI) -0.25 [-1.90, 1.40]
1.4 Martial Arts v Control 1 26 Mean Difference (IV, Fixed, 95% CI) -0.9 [-1.50, -0.30]
2 Functional Reach (cm) 4 393 Mean Difference (IV, Fixed, 95% CI) 2.16 [0.89, 3.43]
2.1 Exercise v Control 3 240 Mean Difference (IV, Fixed, 95% CI) 2.46 [0.94, 3.97]
2.2 Cueing v Control 1 153 Mean Difference (IV, Fixed, 95% CI) 1.46 [-0.88, 3.80]
3 Berg Balance Scale 4 361 Mean Difference (IV, Fixed, 95% CI) 3.36 [1.91, 4.81]
3.1 Exercise v Control 2 256 Mean Difference (IV, Fixed, 95% CI) 1.59 [-0.90, 4.07]
3.2 Treadmill v Control 1 31 Mean Difference (IV, Fixed, 95% CI) 8.29 [1.07, 15.51]
3.3 Dance v Control 1 48 Mean Difference (IV, Fixed, 95% CI) 5.15 [0.42, 9.88]
3.4 Martial Arts v Control 1 26 Mean Difference (IV, Fixed, 95% CI) 3.80 [1.81, 5.79]
4 Activity Specific Balance
Confidence
3 66 Mean Difference (IV, Fixed, 95% CI) 2.40 [-2.78, 7.57]
4.1 Exercise v Control 2 38 Mean Difference (IV, Fixed, 95% CI) 3.63 [-2.09, 9.36]
4.2 Cueing v Control 1 28 Mean Difference (IV, Fixed, 95% CI) -3.1 [-15.18, 8.98]
Comparison 3. Falls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Falls Efficacy Scale 4 353 Mean Difference (IV, Fixed, 95% CI) -1.91 [-4.76, 0.94]
1.1 Exercise v Control 3 200 Mean Difference (IV, Fixed, 95% CI) -2.53 [-5.55, 0.48]
1.2 Cueing v Control 1 153 Mean Difference (IV, Fixed, 95% CI) 3.32 [-5.38, 12.02]
Comparison 4. Clinician-Rated Disability
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 UPDRS - Total 2 105 Mean Difference (IV, Fixed, 95% CI) -4.46 [-7.16, -1.75]
1.1 General Physiotherapy v
Control
2 85 Mean Difference (IV, Fixed, 95% CI) -4.84 [-7.63, -2.04]
1.2 Treadmill v Control 1 20 Mean Difference (IV, Fixed, 95% CI) 1.1 [-9.60, 11.80]
2 UPDRS - Mental 2 105 Mean Difference (IV, Fixed, 95% CI) -0.44 [-0.98, 0.09]
2.1 General Physiotherapy v
Control
2 85 Mean Difference (IV, Fixed, 95% CI) -0.47 [-1.05, 0.11]
2.2 Treadmill v Control 1 20 Mean Difference (IV, Fixed, 95% CI) -0.3 [-1.64, 1.04]
3 UPDRS - ADL 3 157 Mean Difference (IV, Fixed, 95% CI) -1.36 [-2.41, -0.30]
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3.1 General Physiotherapy v
Control
2 85 Mean Difference (IV, Fixed, 95% CI) -1.62 [-2.77, -0.47]
3.2 Treadmill v Control 1 20 Mean Difference (IV, Fixed, 95% CI) 1.50 [-1.81, 4.81]
3.3 Dance v Control 1 52 Mean Difference (IV, Fixed, 95% CI) -2.50 [-6.83, 1.83]
4 UPDRS - Motor 9 431 Mean Difference (IV, Fixed, 95% CI) -4.09 [-5.59, -2.59]
4.1 General Physiotherapy v
Control
3 137 Mean Difference (IV, Fixed, 95% CI) -3.08 [-5.24, -0.92]
4.2 Exercise v Control 1 46 Mean Difference (IV, Fixed, 95% CI) -4.9 [-9.51, -0.29]
4.3 Treadmill v Control 1 20 Mean Difference (IV, Fixed, 95% CI) -0.10 [-7.96, 7.76]
4.4 Cueing v Control 2 50 Mean Difference (IV, Fixed, 95% CI) -4.58 [-9.02, -0.15]
4.5 Dance v Control 2 100 Mean Difference (IV, Fixed, 95% CI) -6.17 [-10.52, -1.83]
4.6 Martial Arts v Control 2 78 Mean Difference (IV, Fixed, 95% CI) -5.82 [-9.79, -1.85]
Comparison 5. Patient-Rated Quality of Life
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PDQ-39 Summary Index 6 387 Mean Difference (IV, Fixed, 95% CI) -0.35 [-2.66, 1.96]
1.1 General Physiotherapy v
Control
1 52 Mean Difference (IV, Fixed, 95% CI) 0.68 [-6.84, 8.20]
1.2 Exercise v Control 3 104 Mean Difference (IV, Fixed, 95% CI) 0.32 [-3.83, 4.48]
1.3 Cueing v Control 1 153 Mean Difference (IV, Fixed, 95% CI) -1.58 [-5.45, 2.29]
1.4 Dance v Control 1 48 Mean Difference (IV, Fixed, 95% CI) -2.34 [-8.83, 4.15]
1.5 Martial Arts v Control 1 30 Mean Difference (IV, Fixed, 95% CI) 3.05 [-3.81, 9.91]
2 PDQ-39 Mobility 2 105 Mean Difference (IV, Fixed, 95% CI) -1.43 [-8.03, 5.18]
2.1 General Physiotherapy v
Control
1 27 Mean Difference (IV, Fixed, 95% CI) 6.23 [-3.85, 16.31]
2.2 Dance v Control 1 48 Mean Difference (IV, Fixed, 95% CI) -10.41 [-22.50, 1.
68]
2.3 Martial Arts v Control 1 30 Mean Difference (IV, Fixed, 95% CI) -3.65 [-16.30, 9.00]
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Analysis 1.1. Comparison 1 Gait Outcomes, Outcome 1 2- or 6- Minute Walk Test (m).
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 1 Gait Outcomes
Outcome: 1 2- or 6- Minute Walk Test (m)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exercise v Control
Meek 2010 19 6.1 (32.5) 18 0.7 (38.7) 39.4 % 5.40 [ -17.69, 28.49 ]
Schenkman 1998 23 15.4 (35.7) 23 1.9 (42.5) 40.9 % 13.50 [ -9.18, 36.18 ]
Schilling 2008 8 49.2 (76.6) 7 25.1 (75.6) 3.5 % 24.10 [ -53.06, 101.26 ]
Subtotal (95% CI) 50 48 83.8 % 10.14 [ -5.70, 25.97 ]
Heterogeneity: Chi2 = 0.37, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
2 Dance v Control
Hackney 2009 31 54.2 (80.2) 17 -7.5 (127) 4.7 % 61.70 [ -4.95, 128.35 ]
Subtotal (95% CI) 31 17 4.7 % 61.70 [ -4.95, 128.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
3 Martial Arts v Control
Hackney 2009 13 44.4 (65.9) 13 0.8 (43.4) 11.4 % 43.60 [ 0.71, 86.49 ]
Subtotal (95% CI) 13 13 11.4 % 43.60 [ 0.71, 86.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.046)
Total (95% CI) 94 78 100.0 % 16.40 [ 1.90, 30.90 ]
Heterogeneity: Chi2 = 4.29, df = 4 (P = 0.37); I2 =7%
Test for overall effect: Z = 2.22 (P = 0.027)
Test for subgroup differences: Chi2 = 3.92, df = 2 (P = 0.14), I2 =49%
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Analysis 1.2. Comparison 1 Gait Outcomes, Outcome 2 10- or 20- m Walk Test (s).
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 1 Gait Outcomes
Outcome: 2 10- or 20- m Walk Test (s)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exercise v Control
Meek 2010 20 0 (2.2) 18 -0.7 (3.8) 3.9 % 0.70 [ -1.30, 2.70 ]
Schenkman 1998 23 0.1 (0.2) 23 -0.4 (1) 90.3 % 0.50 [ 0.08, 0.92 ]
Stozek 2003 30 -1.3 (1.8) 31 0.2 (4.9) 4.6 % -1.50 [ -3.34, 0.34 ]
Subtotal (95% CI) 73 72 98.8 % 0.41 [ 0.02, 0.81 ]
Heterogeneity: Chi2 = 4.39, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 2.04 (P = 0.042)
2 Treadmill v Control
Kurtais 2008 12 -2.5 (5.2) 12 -1.7 (3.7) 1.2 % -0.80 [ -4.41, 2.81 ]
Subtotal (95% CI) 12 12 1.2 % -0.80 [ -4.41, 2.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.66)
Total (95% CI) 85 84 100.0 % 0.40 [ 0.00, 0.80 ]
Heterogeneity: Chi2 = 4.82, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 1.98 (P = 0.048)
Test for subgroup differences: Chi2 = 0.43, df = 1 (P = 0.51), I2 =0.0%
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Analysis 1.3. Comparison 1 Gait Outcomes, Outcome 3 Velocity (m/s).
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 1 Gait Outcomes
Outcome: 3 Velocity (m/s)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Chandler 1999 26 0.13 (0.36) 26 0.1 (0.3) 1.7 % 0.03 [ -0.15, 0.21 ]
Ellis 2005 32 0.16 (0.22) 33 0.01 (0.21) 5.2 % 0.15 [ 0.05, 0.25 ]
Fisher 2008 10 0.02 (0.18) 10 0.02 (0.17) 2.4 % 0.0 [ -0.15, 0.15 ]
Subtotal (95% CI) 68 69 9.3 % 0.09 [ 0.01, 0.17 ]
Heterogeneity: Chi2 = 3.01, df = 2 (P = 0.22); I2 =34%
Test for overall effect: Z = 2.23 (P = 0.025)
2 Exercise v Control
Allen 2010 21 0.02 (0.27) 24 0.02 (0.29) 2.1 % 0.0 [ -0.16, 0.16 ]
Mak 2008 19 0.02 (0.08) 14 0 (0.06) 24.9 % 0.02 [ -0.03, 0.07 ]
Sage 2009a 31 0.06 (0.2) 15 0 (0.22) 3.3 % 0.06 [ -0.07, 0.20 ]
Thaut 1996 11 0.07 (0.18) 11 -0.05 (0.27) 1.5 % 0.12 [ -0.07, 0.31 ]
Subtotal (95% CI) 82 64 31.8 % 0.03 [ -0.01, 0.07 ]
Heterogeneity: Chi2 = 1.39, df = 3 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
3 Treadmill v Control
Fisher 2008 10 0.06 (0.2) 10 0.02 (0.17) 2.1 % 0.04 [ -0.12, 0.20 ]
Protas 2005 9 0.17 (0.35) 9 0.01 (0.23) 0.8 % 0.16 [ -0.11, 0.43 ]
Subtotal (95% CI) 19 19 2.9 % 0.07 [ -0.07, 0.21 ]
Heterogeneity: Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
4 Cueing v Control
de Bruin 2010a 11 0.03 (0.22) 11 -0.02 (0.17) 2.1 % 0.05 [ -0.11, 0.21 ]
Mak 2008 19 0.05 (0.06) 14 0 (0.06) 33.0 % 0.05 [ 0.01, 0.09 ]
Nieuwboer 2007 76 0.08 (0.16) 77 0.02 (0.23) 14.4 % 0.06 [ 0.00, 0.12 ]
Thaut 1996 15 0.16 (0.22) 11 -0.05 (0.27) 1.5 % 0.21 [ 0.02, 0.40 ]
Subtotal (95% CI) 121 113 51.1 % 0.06 [ 0.02, 0.09 ]
Heterogeneity: Chi2 = 2.50, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 3.38 (P = 0.00072)
5 Dance v Control
-1 -0.5 0 0.5 1
Favours No Intervention Favours Intervention
(Continued . . . )
79Physiotherapy versus placebo or no intervention in Parkinson’s disease (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hackney 2009 31 0.05 (0.2) 17 0.02 (0.38) 1.5 % 0.03 [ -0.16, 0.22 ]
Subtotal (95% CI) 31 17 1.5 % 0.03 [ -0.16, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
6 Martial Arts v Control
Hackney 2009 13 0.01 (0.21) 13 0.1 (0.11) 3.4 % -0.09 [ -0.22, 0.04 ]
Subtotal (95% CI) 13 13 3.4 % -0.09 [ -0.22, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
Total (95% CI) 334 295 100.0 % 0.05 [ 0.02, 0.07 ]
Heterogeneity: Chi2 = 14.19, df = 14 (P = 0.44); I2 =1%
Test for overall effect: Z = 3.79 (P = 0.00015)
Test for subgroup differences: Chi2 = 6.75, df = 5 (P = 0.24), I2 =26%
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Analysis 1.4. Comparison 1 Gait Outcomes, Outcome 4 Cadence (steps/min).
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 1 Gait Outcomes
Outcome: 4 Cadence (steps/min)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Fisher 2008 10 -1.6 (10.9) 10 0.8 (8.9) 6.9 % -2.40 [ -11.12, 6.32 ]
Subtotal (95% CI) 10 10 6.9 % -2.40 [ -11.12, 6.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
2 Exercise v Control
Sage 2009a 31 1.1 (9.2) 15 0 (8.7) 17.6 % 1.10 [ -4.37, 6.57 ]
Thaut 1996 11 -0.4 (8) 11 8.1 (12) 7.3 % -8.50 [ -17.02, 0.02 ]
Subtotal (95% CI) 42 26 24.9 % -1.70 [ -6.30, 2.90 ]
Heterogeneity: Chi2 = 3.45, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 0.72 (P = 0.47)
3 Treadmill v Control
Fisher 2008 10 0.2 (9.6) 10 0.8 (8.9) 8.0 % -0.60 [ -8.71, 7.51 ]
Protas 2005 9 7.5 (7.7) 9 6.6 (14.2) 4.7 % 0.90 [ -9.65, 11.45 ]
Subtotal (95% CI) 19 19 12.7 % -0.04 [ -6.48, 6.39 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
4 Cueing v Control
de Bruin 2010a 11 2 (7.9) 11 1 (12.5) 6.9 % 1.00 [ -7.74, 9.74 ]
Nieuwboer 2007 76 -0.4 (10.2) 77 2.5 (11.9) 42.7 % -2.90 [ -6.41, 0.61 ]
Thaut 1996 15 8.9 (12.6) 11 8.1 (11.96) 5.8 % 0.80 [ -8.72, 10.32 ]
Subtotal (95% CI) 102 99 55.5 % -2.03 [ -5.11, 1.05 ]
Heterogeneity: Chi2 = 1.04, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
Total (95% CI) 173 154 100.0 % -1.72 [ -4.01, 0.58 ]
Heterogeneity: Chi2 = 4.86, df = 7 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Chi2 = 0.32, df = 3 (P = 0.96), I2 =0.0%
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Analysis 1.5. Comparison 1 Gait Outcomes, Outcome 5 Stride Length (m).
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 1 Gait Outcomes
Outcome: 5 Stride Length (m)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Fisher 2008 10 0.02 (0.15) 10 0.04 (0.23) 10.7 % -0.02 [ -0.19, 0.15 ]
Subtotal (95% CI) 10 10 10.7 % -0.02 [ -0.19, 0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
2 Exercise v Control
Thaut 1996 11 0.08 (0.19) 11 -0.09 (0.29) 7.4 % 0.17 [ -0.03, 0.37 ]
Subtotal (95% CI) 11 11 7.4 % 0.17 [ -0.03, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
3 Treadmill v Control
Fisher 2008 10 0.06 (0.17) 10 0.04 (0.23) 9.8 % 0.02 [ -0.16, 0.20 ]
Protas 2005 9 0.04 (0.15) 9 0 (0.13) 18.4 % 0.04 [ -0.09, 0.17 ]
Subtotal (95% CI) 19 19 28.2 % 0.03 [ -0.07, 0.14 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
4 Cueing v Control
de Bruin 2010a 11 0.01 (0.18) 11 -0.03 (0.14) 17.0 % 0.04 [ -0.09, 0.17 ]
Thaut 1996 15 0.11 (0.18) 11 -0.09 (0.29) 8.2 % 0.20 [ 0.01, 0.39 ]
Subtotal (95% CI) 26 22 25.2 % 0.09 [ -0.02, 0.20 ]
Heterogeneity: Chi2 = 1.76, df = 1 (P = 0.18); I2 =43%
Test for overall effect: Z = 1.63 (P = 0.10)
5 Dance v Control
Hackney 2009 31 0.05 (0.2) 17 -0.02 (0.33) 10.5 % 0.07 [ -0.10, 0.24 ]
Subtotal (95% CI) 31 17 10.5 % 0.07 [ -0.10, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
6 Martial Arts v Control
Hackney 2009 13 -0.1 (0.23) 13 0 (0.07) 18.1 % -0.10 [ -0.23, 0.03 ]
Subtotal (95% CI) 13 13 18.1 % -0.10 [ -0.23, 0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
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(. . . Continued)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Total (95% CI) 110 92 100.0 % 0.03 [ -0.02, 0.09 ]
Heterogeneity: Chi2 = 9.13, df = 7 (P = 0.24); I2 =23%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Chi2 = 7.34, df = 5 (P = 0.20), I2 =32%
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Analysis 1.6. Comparison 1 Gait Outcomes, Outcome 6 Step Length (m).
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 1 Gait Outcomes
Outcome: 6 Step Length (m)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Fisher 2008 10 0.01 (0.08) 10 0.03 (0.11) 10.7 % -0.02 [ -0.10, 0.06 ]
Subtotal (95% CI) 10 10 10.7 % -0.02 [ -0.10, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
2 Exercise v Control
Sage 2009a 31 0.03 (0.1) 15 0 (0.11) 17.5 % 0.03 [ -0.04, 0.09 ]
Subtotal (95% CI) 31 15 17.5 % 0.03 [ -0.04, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
3 Treadmill v Control
Fisher 2008 10 0.04 (0.09) 10 0.03 (0.11) 9.8 % 0.01 [ -0.08, 0.10 ]
Subtotal (95% CI) 10 10 9.8 % 0.01 [ -0.08, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
4 Cueing v Control
Nieuwboer 2007 76 0.04 (0.1) 77 0 (0.12) 62.0 % 0.04 [ 0.01, 0.07 ]
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Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 76 77 62.0 % 0.04 [ 0.01, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.24 (P = 0.025)
Total (95% CI) 127 112 100.0 % 0.03 [ 0.00, 0.06 ]
Heterogeneity: Chi2 = 1.86, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.044)
Test for subgroup differences: Chi2 = 1.86, df = 3 (P = 0.60), I2 =0.0%
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Analysis 1.7. Comparison 1 Gait Outcomes, Outcome 7 Freezing of Gait Questionnaire.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 1 Gait Outcomes
Outcome: 7 Freezing of Gait Questionnaire
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exercise v Control
Allen 2010 21 -1.3 (5.5) 24 1.1 (6) 16.2 % -2.40 [ -5.76, 0.96 ]
Subtotal (95% CI) 21 24 16.2 % -2.40 [ -5.76, 0.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
2 Cueing v Control
Nieuwboer 2007 76 -0.95 (4.74) 77 -0.08 (5.09) 75.2 % -0.87 [ -2.43, 0.69 ]
Subtotal (95% CI) 76 77 75.2 % -0.87 [ -2.43, 0.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
3 Dance v Control
Hackney 2009 31 -0.5 (5) 17 1.2 (8.95) 8.6 % -1.70 [ -6.30, 2.90 ]
Subtotal (95% CI) 31 17 8.6 % -1.70 [ -6.30, 2.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
-10 -5 0 5 10
Favours Intervention Favours No Intervention
(Continued . . . )
84Physiotherapy versus placebo or no intervention in Parkinson’s disease (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Total (95% CI) 128 118 100.0 % -1.19 [ -2.54, 0.16 ]
Heterogeneity: Chi2 = 0.71, df = 2 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.085)
Test for subgroup differences: Chi2 = 0.71, df = 2 (P = 0.70), I2 =0.0%
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Analysis 2.1. Comparison 2 Functional Mobility and Balance Outcomes, Outcome 1 Timed Up & Go (s).
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 2 Functional Mobility and Balance Outcomes
Outcome: 1 Timed Up % Go (s)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exercise v Control
Goodwin 2009 61 0.13 (11.09) 62 -0.48 (13.92) 1.0 % 0.61 [ -3.83, 5.05 ]
Klassen 2007 17 -1.3 (2.5) 6 -0.2 (1.85) 5.4 % -1.10 [ -3.00, 0.80 ]
Sage 2009a 31 -0.6 (2.21) 15 0 (2.33) 9.8 % -0.60 [ -2.01, 0.81 ]
Schilling 2008 8 -0.1 (0.7) 7 -0.75 (1.2) 19.0 % 0.65 [ -0.36, 1.66 ]
Stozek 2003 30 -2.36 (2.63) 31 1.1 (7.15) 2.7 % -3.46 [ -6.15, -0.77 ]
Subtotal (95% CI) 147 121 37.9 % -0.22 [ -0.93, 0.50 ]
Heterogeneity: Chi2 = 9.66, df = 4 (P = 0.05); I2 =59%
Test for overall effect: Z = 0.59 (P = 0.55)
2 Dance v Control
Hackney 2009 31 -1.1 (4.31) 17 2 (9.28) 0.9 % -3.10 [ -7.76, 1.56 ]
Subtotal (95% CI) 31 17 0.9 % -3.10 [ -7.76, 1.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
3 Cueing v Control
Nieuwboer 2007 76 -1.59 (4.59) 77 -1.34 (5.78) 7.1 % -0.25 [ -1.90, 1.40 ]
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Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 76 77 7.1 % -0.25 [ -1.90, 1.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
4 Martial Arts v Control
Hackney 2009 13 -1 (0.1) 13 -0.1 (1.1) 54.1 % -0.90 [ -1.50, -0.30 ]
Subtotal (95% CI) 13 13 54.1 % -0.90 [ -1.50, -0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.94 (P = 0.0033)
Total (95% CI) 267 228 100.0 % -0.61 [ -1.06, -0.17 ]
Heterogeneity: Chi2 = 12.99, df = 7 (P = 0.07); I2 =46%
Test for overall effect: Z = 2.73 (P = 0.0064)
Test for subgroup differences: Chi2 = 3.33, df = 3 (P = 0.34), I2 =10%
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Analysis 2.2. Comparison 2 Functional Mobility and Balance Outcomes, Outcome 2 Functional Reach (cm).
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 2 Functional Mobility and Balance Outcomes
Outcome: 2 Functional Reach (cm)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exercise v Control
Ashburn 2007 67 0.4 (6.56) 66 -1 (7) 30.3 % 1.40 [ -0.91, 3.71 ]
Schenkman 1998 23 1.57 (4.45) 23 -0.28 (4.17) 26.0 % 1.85 [ -0.64, 4.34 ]
Stozek 2003 30 5.8 (6.01) 31 -0.03 (7.38) 14.2 % 5.83 [ 2.46, 9.20 ]
Subtotal (95% CI) 120 120 70.5 % 2.46 [ 0.94, 3.97 ]
Heterogeneity: Chi2 = 4.88, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 3.18 (P = 0.0015)
2 Cueing v Control
Nieuwboer 2007 76 1.8 (5.28) 77 0.34 (9.02) 29.5 % 1.46 [ -0.88, 3.80 ]
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(. . . Continued)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 76 77 29.5 % 1.46 [ -0.88, 3.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Total (95% CI) 196 197 100.0 % 2.16 [ 0.89, 3.43 ]
Heterogeneity: Chi2 = 5.37, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 3.34 (P = 0.00085)
Test for subgroup differences: Chi2 = 0.49, df = 1 (P = 0.48), I2 =0.0%
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Analysis 2.3. Comparison 2 Functional Mobility and Balance Outcomes, Outcome 3 Berg Balance Scale.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 2 Functional Mobility and Balance Outcomes
Outcome: 3 Berg Balance Scale
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exercise v Control
Ashburn 2007 67 1.5 (9.51) 66 1.6 (10.21) 18.6 % -0.10 [ -3.45, 3.25 ]
Goodwin 2009 61 3.1 (11.07) 62 -0.55 (9.88) 15.2 % 3.65 [ -0.06, 7.36 ]
Subtotal (95% CI) 128 128 33.8 % 1.59 [ -0.90, 4.07 ]
Heterogeneity: Chi2 = 2.16, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 1.25 (P = 0.21)
2 Treadmill v Control
Cakit 2007 21 7.09 (8.5) 10 -1.2 (10.07) 4.0 % 8.29 [ 1.07, 15.51 ]
Subtotal (95% CI) 21 10 4.0 % 8.29 [ 1.07, 15.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.024)
3 Dance v Control
Hackney 2009 31 3.95 (4.7) 17 -1.2 (9.32) 9.4 % 5.15 [ 0.42, 9.88 ]
Subtotal (95% CI) 31 17 9.4 % 5.15 [ 0.42, 9.88 ]
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Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.033)
4 Martial Arts v Control
Hackney 2009 13 3.3 (3) 13 -0.5 (2.1) 52.8 % 3.80 [ 1.81, 5.79 ]
Subtotal (95% CI) 13 13 52.8 % 3.80 [ 1.81, 5.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.74 (P = 0.00018)
Total (95% CI) 193 168 100.0 % 3.36 [ 1.91, 4.81 ]
Heterogeneity: Chi2 = 6.64, df = 4 (P = 0.16); I2 =40%
Test for overall effect: Z = 4.55 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.48, df = 3 (P = 0.21), I2 =33%
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Analysis 2.4. Comparison 2 Functional Mobility and Balance Outcomes, Outcome 4 Activity Specific
Balance Confidence.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 2 Functional Mobility and Balance Outcomes
Outcome: 4 Activity Specific Balance Confidence
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exercise v Control
Klassen 2007 17 1.75 (6.76) 6 -1.7 (6.87) 66.0 % 3.45 [ -2.92, 9.82 ]
Schilling 2008 8 3.3 (8.35) 7 -1.1 (15.85) 15.6 % 4.40 [ -8.69, 17.49 ]
Subtotal (95% CI) 25 13 81.6 % 3.63 [ -2.09, 9.36 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.21)
2 Cueing v Control
Shankar 2008 14 -2.1 (16.5) 14 1 (16.1) 18.4 % -3.10 [ -15.18, 8.98 ]
Subtotal (95% CI) 14 14 18.4 % -3.10 [ -15.18, 8.98 ]
Heterogeneity: not applicable
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Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 0.50 (P = 0.61)
Total (95% CI) 39 27 100.0 % 2.40 [ -2.78, 7.57 ]
Heterogeneity: Chi2 = 0.99, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 0.97, df = 1 (P = 0.32), I2 =0.0%
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Analysis 3.1. Comparison 3 Falls, Outcome 1 Falls Efficacy Scale.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 3 Falls
Outcome: 1 Falls Efficacy Scale
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exercise v Control
Allen 2010 21 -2.3 (10.6) 24 1.3 (10.56) 21.1 % -3.60 [ -9.80, 2.60 ]
Cakit 2007 21 -12.27 (39.06) 10 2.4 (28.78) 1.4 % -14.67 [ -39.11, 9.77 ]
Goodwin 2009 61 -0.83 (9.82) 63 1.12 (9.98) 66.8 % -1.95 [ -5.44, 1.54 ]
Subtotal (95% CI) 103 97 89.3 % -2.53 [ -5.55, 0.48 ]
Heterogeneity: Chi2 = 1.17, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.65 (P = 0.099)
2 Cueing v Control
Nieuwboer 2007 76 4.48 (25.37) 77 1.16 (29.44) 10.7 % 3.32 [ -5.38, 12.02 ]
Subtotal (95% CI) 76 77 10.7 % 3.32 [ -5.38, 12.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
Total (95% CI) 179 174 100.0 % -1.91 [ -4.76, 0.94 ]
Heterogeneity: Chi2 = 2.72, df = 3 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 1.55, df = 1 (P = 0.21), I2 =36%
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Analysis 4.1. Comparison 4 Clinician-Rated Disability, Outcome 1 UPDRS - Total.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 4 Clinician-Rated Disability
Outcome: 1 UPDRS - Total
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Ellis 2005 32 -6.2 (6.2) 33 -1 (6) 82.9 % -5.20 [ -8.17, -2.23 ]
Fisher 2008 10 -5.2 (8.72) 10 -3.2 (10.1) 10.7 % -2.00 [ -10.27, 6.27 ]
Subtotal (95% CI) 42 43 93.6 % -4.84 [ -7.63, -2.04 ]
Heterogeneity: Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 3.39 (P = 0.00069)
2 Treadmill v Control
Fisher 2008 10 -2.1 (14) 10 -3.2 (10.1) 6.4 % 1.10 [ -9.60, 11.80 ]
Subtotal (95% CI) 10 10 6.4 % 1.10 [ -9.60, 11.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 52 53 100.0 % -4.46 [ -7.16, -1.75 ]
Heterogeneity: Chi2 = 1.62, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 3.23 (P = 0.0012)
Test for subgroup differences: Chi2 = 1.11, df = 1 (P = 0.29), I2 =10%
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Analysis 4.2. Comparison 4 Clinician-Rated Disability, Outcome 2 UPDRS - Mental.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 4 Clinician-Rated Disability
Outcome: 2 UPDRS - Mental
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Ellis 2005 32 -1.1 (1.6) 33 -0.5 (1.3) 56.7 % -0.60 [ -1.31, 0.11 ]
Fisher 2008 10 0.1 (1.37) 10 0.3 (0.91) 27.5 % -0.20 [ -1.22, 0.82 ]
Subtotal (95% CI) 42 43 84.2 % -0.47 [ -1.05, 0.11 ]
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.58 (P = 0.11)
2 Treadmill v Control
Fisher 2008 10 0 (1.97) 10 0.3 (0.91) 15.8 % -0.30 [ -1.64, 1.04 ]
Subtotal (95% CI) 10 10 15.8 % -0.30 [ -1.64, 1.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Total (95% CI) 52 53 100.0 % -0.44 [ -0.98, 0.09 ]
Heterogeneity: Chi2 = 0.45, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.62 (P = 0.10)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 4.3. Comparison 4 Clinician-Rated Disability, Outcome 3 UPDRS - ADL.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 4 Clinician-Rated Disability
Outcome: 3 UPDRS - ADL
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Ellis 2005 32 -2.1 (2.8) 33 -0.3 (2.3) 71.4 % -1.80 [ -3.05, -0.55 ]
Fisher 2008 10 -1.5 (2.81) 10 -0.9 (3.9) 12.5 % -0.60 [ -3.58, 2.38 ]
Subtotal (95% CI) 42 43 83.9 % -1.62 [ -2.77, -0.47 ]
Heterogeneity: Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.76 (P = 0.0058)
2 Treadmill v Control
Fisher 2008 10 0.6 (3.64) 10 -0.9 (3.9) 10.2 % 1.50 [ -1.81, 4.81 ]
Subtotal (95% CI) 10 10 10.2 % 1.50 [ -1.81, 4.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
3 Dance v Control
Earhart 2010 26 -0.6 (7.5) 26 1.9 (8.4) 5.9 % -2.50 [ -6.83, 1.83 ]
Subtotal (95% CI) 26 26 5.9 % -2.50 [ -6.83, 1.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
Total (95% CI) 78 79 100.0 % -1.36 [ -2.41, -0.30 ]
Heterogeneity: Chi2 = 3.87, df = 3 (P = 0.28); I2 =22%
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Chi2 = 3.34, df = 2 (P = 0.19), I2 =40%
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Analysis 4.4. Comparison 4 Clinician-Rated Disability, Outcome 4 UPDRS - Motor.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 4 Clinician-Rated Disability
Outcome: 4 UPDRS - Motor
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Chandler 1999 26 -1 (7) 26 3 (6.24) 17.3 % -4.00 [ -7.60, -0.40 ]
Ellis 2005 32 -3 (6.6) 33 -0.2 (5.3) 26.5 % -2.80 [ -5.72, 0.12 ]
Fisher 2008 10 -3.8 (8.17) 10 -2.7 (8.15) 4.4 % -1.10 [ -8.25, 6.05 ]
Subtotal (95% CI) 68 69 48.1 % -3.08 [ -5.24, -0.92 ]
Heterogeneity: Chi2 = 0.58, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.79 (P = 0.0053)
2 Exercise v Control
Sage 2009a 31 -3.7 (6.72) 15 1.2 (7.81) 10.6 % -4.90 [ -9.51, -0.29 ]
Subtotal (95% CI) 31 15 10.6 % -4.90 [ -9.51, -0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.08 (P = 0.037)
3 Treadmill v Control
Fisher 2008 10 -2.8 (9.72) 10 -2.7 (8.15) 3.6 % -0.10 [ -7.96, 7.76 ]
Subtotal (95% CI) 10 10 3.6 % -0.10 [ -7.96, 7.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
4 Cueing v Control
de Bruin 2010a 11 -5.6 (9.17) 11 -1.8 (6.53) 5.1 % -3.80 [ -10.45, 2.85 ]
Shankar 2008 14 -4 (8.29) 14 1.21 (7.75) 6.4 % -5.21 [ -11.15, 0.73 ]
Subtotal (95% CI) 25 25 11.4 % -4.58 [ -9.02, -0.15 ]
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.03 (P = 0.043)
5 Dance v Control
Earhart 2010 26 -5.4 (11.9) 26 -0.1 (10.3) 6.1 % -5.30 [ -11.35, 0.75 ]
Hackney 2009 31 -2.1 (10.96) 17 5 (10.33) 5.8 % -7.10 [ -13.34, -0.86 ]
Subtotal (95% CI) 57 43 11.9 % -6.17 [ -10.52, -1.83 ]
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 2.78 (P = 0.0054)
6 Martial Arts v Control
Hackney 2009 13 -1.5 (6.6) 13 4.3 (5.6) 10.2 % -5.80 [ -10.51, -1.09 ]
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(. . . Continued)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schmitz-Hubsch 2006 31 -0.32 (10.9) 21 5.54 (14.77) 4.1 % -5.86 [ -13.25, 1.53 ]
Subtotal (95% CI) 44 34 14.3 % -5.82 [ -9.79, -1.85 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 2.87 (P = 0.0041)
Total (95% CI) 235 196 100.0 % -4.09 [ -5.59, -2.59 ]
Heterogeneity: Chi2 = 4.45, df = 10 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 5.35 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.61, df = 5 (P = 0.61), I2 =0.0%
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Analysis 5.1. Comparison 5 Patient-Rated Quality of Life, Outcome 1 PDQ-39 Summary Index.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 5 Patient-Rated Quality of Life
Outcome: 1 PDQ-39 Summary Index
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Chandler 1999 26 4 (14.94) 26 3.32 (12.65) 9.4 % 0.68 [ -6.84, 8.20 ]
Subtotal (95% CI) 26 26 9.4 % 0.68 [ -6.84, 8.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
2 Exercise v Control
Allen 2010 21 -1 (14.3) 24 4.9 (26.7) 3.5 % -5.90 [ -18.21, 6.41 ]
Klassen 2007 17 0.25 (4.06) 6 -1 (5.54) 22.9 % 1.25 [ -3.58, 6.08 ]
Meek 2010 19 -2.6 (15.6) 17 -3.1 (17.42) 4.5 % 0.50 [ -10.35, 11.35 ]
Subtotal (95% CI) 57 47 30.9 % 0.32 [ -3.83, 4.48 ]
Heterogeneity: Chi2 = 1.12, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
3 Cueing v Control
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Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nieuwboer 2007 76 -3.42 (11.08) 77 -1.84 (13.28) 35.6 % -1.58 [ -5.45, 2.29 ]
Subtotal (95% CI) 76 77 35.6 % -1.58 [ -5.45, 2.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
4 Dance v Control
Hackney 2009 31 -3.84 (5.4) 17 -1.5 (13.05) 12.7 % -2.34 [ -8.83, 4.15 ]
Subtotal (95% CI) 31 17 12.7 % -2.34 [ -8.83, 4.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
5 Martial Arts v Control
Hackney 2009 13 1.55 (5.37) 17 -1.5 (13.05) 11.4 % 3.05 [ -3.81, 9.91 ]
Subtotal (95% CI) 13 17 11.4 % 3.05 [ -3.81, 9.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
Total (95% CI) 203 184 100.0 % -0.35 [ -2.66, 1.96 ]
Heterogeneity: Chi2 = 2.99, df = 6 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Chi2 = 1.87, df = 4 (P = 0.76), I2 =0.0%
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Analysis 5.2. Comparison 5 Patient-Rated Quality of Life, Outcome 2 PDQ-39 Mobility.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 5 Patient-Rated Quality of Life
Outcome: 2 PDQ-39 Mobility
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Keus 2007b 14 4.11 (14.5) 13 -2.12 (12.2) 42.9 % 6.23 [ -3.85, 16.31 ]
Subtotal (95% CI) 14 13 42.9 % 6.23 [ -3.85, 16.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
2 Dance v Control
Hackney 2009 31 -5.99 (8.95) 17 4.42 (24.56) 29.8 % -10.41 [ -22.50, 1.68 ]
Subtotal (95% CI) 31 17 29.8 % -10.41 [ -22.50, 1.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.092)
3 Martial Arts v Control
Hackney 2009 13 0.77 (8.94) 17 4.42 (24.56) 27.3 % -3.65 [ -16.30, 9.00 ]
Subtotal (95% CI) 13 17 27.3 % -3.65 [ -16.30, 9.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 58 47 100.0 % -1.43 [ -8.03, 5.18 ]
Heterogeneity: Chi2 = 4.45, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Chi2 = 4.45, df = 2 (P = 0.11), I2 =55%
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Table 1. Key Characteristics of Studies
Study Number
Ran-
domised
Mean
Age (yrs)
Mean
Hoehn
& Yahr
Stage
Duration
of
Disease
(yrs)
% Male Durationof
Treatment
Design Location Type of
Treatment
Allen 2010 48 67 8 54 48-72hrs/
24 weeks
Parallel Outpatient Exercise
Ashburn
2007
142 72.15 3.13 8.35 61 42hrs/6
weeks
Parallel Home Exercise
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Table 1. Key Characteristics of Studies (Continued)
Cakit
2007
54 71.8 5.58 52 30 mins
sessions/ 8
weeks
Parallel Outpatient Treadmill
Canning
2008
20 61 9-12hrs/6
weeks
Parallel Home Treadmill
Cerri 1994 6 15hrs/3
weeks
Parallel Outpa-
tient/Home
Exercise
Chandler
1999
67 65.5 2.6 60 5 times/52
weeks
Parallel Home Physio
de Bruin
2010a
22 65.6 2.2 5.5 50 18hrs/12
weeks
Parallel Outpatient Cueing
de Bruin
2010b
13 3 per week/
13 weeks
Parallel Outpatient Cueing
Earhart
2010
62 70.3 2.5 56 24hrs/2
weeks
Parallel Dance
Ellis 2005 68 64 2.4 75 18hrs/6
weeks
Cross-over Outpatient Physio
Fisher
2008
30 62.9 1.9 1.1 63 24 sessions/
8 weeks
Parallel Outpatient Treadmill/
Physio
Ganesan
2010
20 8hrs/4
weeks
Parallel Outpatient Treadmill
Goodwin
2009
130 71.1 2.5 8.7 57 10 weeks Parallel Outpatient Exercise
Hackney
2009
75 66.6 2.1 7.7 74 20hrs/13
weeks
Parallel Outpatient Dance/
Martial Arts
Homann
1998
15 14 units/5
weeks
Parallel Outpatient Physio
Keus 2007 27 67.95 2.4 6.5 81 1 or
2 per week/
10 weeks
Parallel Outpatient Physio
Klassen
2007
26 66.2 1.6 4.7 74 15-30hrs/
12 weeks
Parallel Outpatient Exercise
Kurtais
2008
27 64.75 2.1 5 50 12hrs/6
weeks
Parallel Outpatient Treadmill
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Table 1. Key Characteristics of Studies (Continued)
Lehman
2005
11 75.8 6.5 73 5 per week/
2 weeks
Parallel Outpatient Cueing
Mak 2008 60 64 2.7 6 4-6hrs/4
weeks
Parallel Outpatient Cueing/
Exercise
Marjama-
Lyons
2002
30 24hrs/12
weeks
Parallel Outpatient Martial Arts
Meek
2010
39 64.2 4.9 79 12 weeks Parallel Outpatient Exercise
Nieuw-
boer 2007
153 67.1 2.8 7.5 58 4.5hrs/3
weeks
Cross-over Home Cueing
Protas
2005
18 72.5 2.9 7.6 100 24hrs/8
weeks
Parallel Outpatient Treadmill
Purchas
2007
20 70 2.15 61 12hrs/12
weeks
Cross-over Martial Arts
Sage 2009a 53 66 3.5 54 18-24hrs/
10-12
weeks
Parallel Outpatient Exercise
Schenkman
1998
51 70.9 2.7 74 22.5-30rs/
10 weeks
Parallel Outpatient Exercise
Schilling
2008
18 59.2 2 61 2 per week/
8 weeks
Parallel Outpatient Exercise
Schmitz-
Hubsch
2006
56 63.5 5.8 77 16hrs/24
weeks
Parallel Outpatient Martial Arts
Shankar
2008
28 66 2.4 7.7 50 18hrs/12
weeks
Parallel Outpatient Cueing
Shankar
2009
20 8hrs/8
weeks
Parallel Outpatient Treadmill
Stozek
2003
61 65.5 2.3 4.5 48 56hrs/4
weeks
Parallel Outpatient Exercise
Thaut
1996
37 71.3 2.5 7.7 70 10.5hrs/3
weeks
Parallel Home Exercise/
Cueing
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